matchedPattern,context,lineNumber,columnNumber,publicationName
p.G193S,"mutation, p.G193S, causing fatal infantile cardioencephalomy...",289,11,Acta_Myol_2011_Jul_30(1)_9-15.txt
p.T378P,...harbored the same previously unreported mutation (p.T378P) that we had identified in our latest pati...,98,294,Acta_Myol_2011_Oct_30(2)_96-102.txt
p.V600E,"...quently found in cutaneous melanomas (c.1799 T>A, p.V600E), raising the question whether this is a m...",3,2201,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Pro,...able 3). All mutations were present in codon 209 (p.Gln209Pro and p.Gln209Leu) and were somatic muta...,81,162,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Leu,...ations were present in codon 209 (p.Gln209Pro and p.Gln209Leu) and were somatic mutations (Fig. 2). ...,81,178,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.V600E,"...BRAF gene revealed one BRAF mutation (c.1799 T>A, p.V600E), in a melanoma. No HRAS or NRAS mutations...",81,801,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Pro,3	MC	c.626 A>C (p.Gln209Pro)	wt	wt	wt,86,17,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Pro,7	MC	c.626 A>C (p.Gln209Pro)	wt	wt	wt,90,17,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Pro,9	MC	c.626 A>C (p.Gln209Pro)	wt	na	wt,92,17,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Leu,10	MM	c.626 A>T (p.Gln209Leu)	wt	wt	na,93,18,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Leu,12	MC	c.626 A>T (p.Gln209Leu)	wt	na	na,95,18,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Leu,13	MC	c.626 A>T (p.Gln209Leu)	wt	wt	na,96,18,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Gln209Leu,14	MC	c.626 A>T (p.Gln209Leu)	wt	wt	wt,97,18,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.V600E,15	MM	wt	c.1799 T>A (p.V600E)	na	wt,98,22,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.V600E,"... with a BRAF point mutation (case 15; c.1799 T>A, p.V600E) might be a metastasis rather than a prima...",114,857,Acta_Neuropathol_2010_Mar_22_119(3)_317-323.txt
p.Val600Glu,... Kular J Millward M Iacopetta B Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecu...,152,68,Acta_Neuropathol_Commun_2013_May_30_1_20.txt
p.Val600Lys,...d M Iacopetta B Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 1...,152,84,Acta_Neuropathol_Commun_2013_May_30_1_20.txt
p.V600E,...l S Cote JF Peschaud F Capper D Detection of BRAF p.V600E mutations in melanomas: comparison of four...,162,128,Acta_Neuropathol_Commun_2013_May_30_1_20.txt
p.Glu5845Glu,....13066delT; p.Tyr4356Thrfs*8 ex110; c.17535G > A; p.Glu5845Glu	exon 86: frameshift mutation leading ...,39,365,Acta_Neuropathol_Commun_2014_Apr_12_2_44.txt
p.Gly6976Gly,...acheostomy.	Yes From 1 month	ex139; c.20928G > T; p.Gly6976Gly	RTPCR and Sanger sequencing of cDNA s...,46,389,Acta_Neuropathol_Commun_2014_Apr_12_2_44.txt
p.Ser8193Ser,"...non-invasive ventilation.	No	ex175; c.24579G > A, p.Ser8193Ser ex119; c.18676C > T, p.Gln6226*	ex175...",50,383,Acta_Neuropathol_Commun_2014_Apr_12_2_44.txt
p.Ala2130Pro,"...43_10046del, p.Val3348Alafs *43 ex49; c.6388G > C p.Ala2130Pro	ex69: truncating/degrading ex49: miss...",52,322,Acta_Neuropathol_Commun_2014_Apr_12_2_44.txt
p.V600E,"...rs, but in none of the group I tumors, and a BRAF:p.V600E mutation in 43% of group I tumors, but in ...",7,753,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,"... KIAA1549-BRAF fusions are found in PAs, and BRAF:p.V600E mutations are frequently detected in PXAs ...",17,414,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,... frequently detected in PXAs (~70%) [14-19]. BRAF:p.V600E mutations are also present in about one qu...,17,485,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,BRAF: p.V600E,27,7,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,BRAF:p.V600E mutations were detected in 7 of 16 (43%) g...,123,6,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,"...1, RNF130, CLCN6, MKRN1 and GNAI1[17,19,21]. BRAF:p.V600E mutations occur in PXAs (~70%), gangliogli...",133,512,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,...ere unable to show a KIAA1549-BRAF fusion or BRAF:p.V600E mutation. Low-grade neuroepithelial tumors...,133,925,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.R132H,...rs presenting in childhood rarely contain an IDH1:p.R132H mutation. This mutation is regarded as a h...,133,1023,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,...not characterized by KIAA1549-BRAF fusion or BRAF:p.V600E mutation [27],133,1448,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.V600E,"...tures of a classic ganglioglioma, harbored a BRAF:p.V600E mutation. This mutation is the most common...",135,239,Acta_Neuropathol_Commun_2014_Feb_14_2_18.txt
p.Phe93Leu,"...sly reported missense mutation [1, 2], c.279C > G p.Phe93Leu in patient 3s. Patients 1 and 2s had no...",118,117,Acta_Neuropathol_Commun_2015_Jul_25_3_44.txt
p.Phe91Ile,"...atients 1 and 2s had novel mutations, c.271 T > A p.Phe91Ile, and c.273C > G p.Phe91Leu, respectivel...",118,194,Acta_Neuropathol_Commun_2015_Jul_25_3_44.txt
p.Phe91Leu,"...mutations, c.271 T > A p.Phe91Ile, and c.273C > G p.Phe91Leu, respectively, affecting the same amino...",118,221,Acta_Neuropathol_Commun_2015_Jul_25_3_44.txt
p.K510E,"...gically, including cases with the newly described p.K510E mutation and a case with both a known p.P5...",5,897,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,...bed p.K510E mutation and a case with both a known p.P525L mutation in the FUS gene and a truncating ...,5,943,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,...p.P525L mutation in the FUS gene and a truncating p.Y374X mutation in the TARDBP gene,5,993,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,...ARDBP with one exception. Case 6 harboured both a p.P525L FUS mutation and also a TARDBP p.Y374X tru...,34,627,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,"...red both a p.P525L FUS mutation and also a TARDBP p.Y374X truncation mutation, the latter of which h...",34,666,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,"...r parent of case 6 to test for segregation of the p.P525L and p.Y374X mutations, however, clinical r...",34,906,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,"...case 6 to test for segregation of the p.P525L and p.Y374X mutations, however, clinical records descr...",34,918,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R495X,1	14	c.1483C>T	p.R495X	34	F	9	Yes	Yes	L	No,37,16,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510E,2	14	c.1528A>G	p.K510E	39	M	15	Yes	Yes	B	No,38,16,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521C,3	15	c.1561C>T	p.R521C	33	M	10	NA	Yes	NA	No,39,16,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521C,4†	15	c.1561C>T	p.R521C	35	F	7	Yes	Yes	B	No†,40,17,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521H,5	15	c.1562G>A	p.R521H	35	F	>36	NA	Yes	L	No,41,16,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R514G,7	15	c.1540A>G	p.R514G	60	M	>96	NA	Yes	B	No,45,16,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,aCase 6 also carried a previously described p.Y374X TARDBP mutation (cDNA position c.1119_1120...,49,45,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521H,...l surviving angulated neurons (arrows) in case 5 (p.R521H). H&E. b Well circumscribed basophilic inc...,121,136,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,...ion (arrow) in an anterior horn neuron in case 6 (p.P525L and p.Y374X TARDBP mutation). This contras...,121,239,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,...in an anterior horn neuron in case 6 (p.P525L and p.Y374X TARDBP mutation). This contrasts with an a...,121,251,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510E,...sophilic aggregate-like inclusions (inset-case 2 (p.K510E)) which resemble condensed Nissl substance...,121,389,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R495X,...in the anterior horns of the spinal cord. Case 1 (p.R495X). Anti p62. d-f. Reveal the differing shap...,121,582,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R495X,"...e anterior horns of the spinal cords in case 1 (d-p.R495X), case 2 (e-p.K510E), and case 4 (f-p.R521...",121,756,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510E,"...the spinal cords in case 1 (d-p.R495X), case 2 (e-p.K510E), and case 4 (f-p.R521C). Anti-FUS. Scale ...",121,776,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521C,"... 1 (d-p.R495X), case 2 (e-p.K510E), and case 4 (f-p.R521C). Anti-FUS. Scale Bar (a)-140 μm, (b) (c) ...",121,800,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510E,...n the anterior horn of the spinal cord in case 2 (p.K510E) with remnants of FUS immunopositivity. An...,124,89,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,...ts of FUS immunopositivity. Anti-FUS. b-e Case 6 (p.P525L and p.Y374X TARDBP mutation) also does exh...,124,159,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,...munopositivity. Anti-FUS. b-e Case 6 (p.P525L and p.Y374X TARDBP mutation) also does exhibit FUS-imm...,124,171,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R495X,... and anti-p62 in (e) inset. f The cord in case 1 (p.R495X) revealing very mild loss of myelin in the...,124,807,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,Fig. 3 Case 6 (p.P525L and p.Y374X TARDBP mutation) (a) and inset...,126,16,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,Fig. 3 Case 6 (p.P525L and p.Y374X TARDBP mutation) (a) and inset illustrates...,126,28,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,"...ilarly Baumer et al. illustrated 2 cases with the p.P525L mutation, one of whom had no UMN features ...",135,1549,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510M,...uffering from a locked-in state associated with a p.K510M mutation and abundant FUS pathology in the...,135,2417,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521C,...ed UMN pathology but this time in patients with a p.R521C mutation which is identical to our cases 3...,135,2612,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,...ous basophilic inclusions (including 2 cases with p.P525L mutations) tended to have a more rapid dis...,135,3215,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521C,"...t, and slower progression (including 2 cases with p.R521C mutations). Our findings do not fit neatly...",135,3462,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R521H,...nto this distinct grouping. Whereas case 5 with a p.R521H mutation would certainly appear to partial...,135,3564,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,...neuronal loss present in the cord. Case 6 (with a p.P525L mutation) also had moderate-large numbers ...,135,4214,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.P525L,"...ed this, in that this patient as well as having a p.P525L mutation also had a truncating p.Y374X TAR...",135,4494,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,...s having a p.P525L mutation also had a truncating p.Y374X TARDBP mutation on chromosome 1. The patho...,135,4533,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.Y374X,.... Daoud et al. have described the genetics of the p.Y374X TARDBP mutation and have predicted this to...,135,5525,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510E,...ption of a patient with ALS-FUS associated with a p.K510E mutation. Syriani et al. described the cli...,137,107,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.R514G,The p.R514G missense mutation again has been detected ...,139,5,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.K510M,...ra S   A Japanese patient with familial ALS and a p.K510M mutation in the gene for FUS (FUS) resulti...,184,150,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.N352S,...anese familial amyotrophic lateral sclerosis with p.N352S mutation in TARDBP Neuropathol Appl Neurob...,187,179,Acta_Neuropathol_Commun_2015_Oct_9_3_62.txt
p.A31P,...iomyopathy in young Maine Coon cats caused by the p.A31P cMyBP-C mutation - the clinical significanc...,3,196,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...tution of an alanine for a proline at residue 31 (p.A31P) of cMyBP-C. The pattern of inheritance has...,4,263,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...cance of being homozygous or heterozygous for the p.A31P cMyBP-C mutation in young to middle-aged ca...,4,704,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...lood samples or buccal swabs and screened for the p.A31P cMyBP-C mutation in exon 3 of the gene, usi...",7,197,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...s that were homozygous for the mutation had fHCM. p.A31P heterozygosity was not associated with a si...,10,360,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...ar that most MC cats that develop fHCM due to the p.A31P mutation prior to the age of approximately ...,13,255,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...tution of an alanine for a proline at residue 31 (p.A31P) of the cMyBP-C protein. Affected cats exhi...,22,217,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...M and MC cats heterozygous and homozygous for the p.A31P cMyBP-C mutation in a large cohort of MC ca...,24,126,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,The p.A31P cMyBP-C genotype of all cats was unknown to...,32,5,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...ed significance. The clinical significance of the p.A31P cMyBP-C protein mutation was determined by ...,38,185,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...es. There was tendency to an increasing effect of p.A31P cMyBP-C homozygosity with age, though the t...",44,255,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...1, P = 0.09. There was only a low effect of being p.A31P cMyBP-C heterozygous, ρ = 0.09, P = 0.4. Bo...",44,391,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...e corresponding line of tendency. Green indicates p.A31P cMyBP-C heterozygous coordinates and the co...,44,708,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...he corresponding line of tendency. Blue indicates p.A31P cMyBP-C homozygous where and the correspond...,44,803,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...according to their fHCM clinical presentation and p.A31P cMyBP-C, respectively",48,417,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,cMyBP-C p.A31P genotype	P-value mutation negative vs,73,10,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...quivocal and the fHCM positive cats in respect to p.A31P genotype,97,99,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,cMyBP-C p.A31P genotype	P-value,107,10,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,p.A31P cMyBP-C genotypin,132,1,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...butions of fHCM and equivocal cases in respect to p.A31P cMyBP-C genotype status. A: Histogram of th...,135,66,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,... distribution for the entire cohort. The group of p.A31P cMyBP-C homozygous cats had an increased pr...,135,167,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,The significance of the p.A31P cMyBP-C mutatio,139,25,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...lated for heterozygous and homozygous carriers of p.A31P cMyBP-C between fHCM affected and non-affec...,140,188,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...rozygous cats were classified as equivocal. Among p.A31P cMyBP-C homozygous MC cats, 50% had fHCM an...",142,145,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...f diastolic IVS and LVFW as a function of age and p.A31P cMyBP-C heterozygous or homozygous status. ...,157,116,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...examine the significance of being affected by the p.A31P cMyBP-C mutation in middle-aged cats. The s...,159,172,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...n of fHCM and equivocal cats as a function of the p.A31P cMyBP-C genotype is shown in Figure 4B. Tab...,159,911,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...cance of being heterozygous or homozygous for the p.A31P cMyBP-C mutation in a cohort of young MC ca...,162,87,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,... thickness had a tendency to progress with age in p.A31P cMyBP-C homozygous cats compared to heteroz...,164,92,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...zygous. Again, no significant association between p.A31P cMyBP-C and fHCM was found in heterozygous ...",166,314,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...d in heterozygous cats. This again indicated that p.A31P cMyBP-C associated fHCM was a disease with ...,166,396,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,... homozygous for the mutation. We propose that the p.A31P cMyBP-C mutation results in an inheritance ...,166,602,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,".... Very recently, Wess et al. [11] stated that the p.A31P mutation is less pathogenic than reported s...",168,480,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...ociated HCM [22]. It can not be excluded that the p.A31P cMyBP-C mutation may exhibit a dominant pat...,170,188,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...at those pedigrees with cats heterozygous for the p.A31P mutation and affected with fHCM may represe...,170,467,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...her yet undiscovered mutation is present with the p.A31P cMyBP-C mutation. Digenic or compound heter...,170,627,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,The p.A31P cMyBP-C genotype distribution was not in Ha...,180,5,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...umber of homozygous cats, which supports that the p.A31P cMyBP-C mutation was disease-causing and re...",180,270,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...roduction. That the prevalence of fHCM and of the p.A31P cMyBP-C mutation found in our cohort is sim...,180,885,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"In conclusion, p.A31P cMyBP-C associated fHCM is a disease with v...",183,16,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,... cats. Our results support the pathogenic role of p.A31P when two affected gene alleles are present ...,183,156,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,...to the high probability of developing fHCM in the p.A31P cMyBP-C homozygous cats the 'production' of...,183,556,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,"...ould be avoided. Thus, although genotyping of the p.A31P cMyBP-C mutation can not stand alone in lim...",183,678,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.A31P,... left ventricular inner diameter; MC: Maine Coon; p.A31P: alanine substituted for a proline at resid...,186,407,Acta_Vet_Scand_2011_Feb_9_53(1)_7.txt
p.Thr328Lys,...ith affected women and men is associated with the p.Thr328Lys mutation in the F12 gene J Allergy Cli...,168,169,Allergy_Asthma_Clin_Immunol_2010_Jul_28_6(1)_15.txt
p.A53T,"...triplications [72] or the SNCA missense mutation, p.A53T [73]. A number of other early-onset familie...",59,313,Alzheimers_Res_Ther_2013_Jul_31_5(Suppl_1)_S7.txt
p.T185S,"... [13,14]. A nonsynonymous SNP numbered rs3173615 (p.T185S) located in exon 6 of the TMEM106B gene sh...",18,956,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,...fibrillary degeneration)	pTDP-43 immunoreactivity	p.T185S genotype,28,178,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,"...n the frontal cortex and the hippocampus, and the p.T185S genotype of the rs3173615 single nucleotid...",55,454,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,p.T185S genotypin,65,1,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,The rs3173615 SNP composed of p.T185S (C760G) in exon 6 of the human TMEM106B ge...,66,31,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,"...able 1. Before starting this, we investigated the p.T185S genotype of rs3173615 in the human TMEM106...",89,243,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,"...e disequilibrium with the coding rs3173615 SNP of p.T185S, is closely associated with FTLD-TDP in th...",124,115,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,"... showing the complete linkage disequilibrium with p.T185S on rs3173615 [3,13,15], is reduced in AD c...",130,152,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,Showing p.T185S genotyping analysis. The rs3173615 SNP com...,150,9,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,...enotyping analysis. The rs3173615 SNP composed of p.T185S (C760G) in exon 6 of the human TMEM106B ge...,150,68,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.T185S,...Graff-Radford NR Dickson DW Rademakers R TMEM106B p.T185S regulates TMEM106B protein levels: implica...,179,221,Alzheimers_Res_Ther_2014_Mar_31_6(2)_17.txt
p.G130A,"...with a heterozygous mutation in SOX2 (c.389G > C, p.G130A) [Kelberman et al., 2006] makes this anoth...",22,103,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.A242T,"Exon 3	Chr9: 125,817,622	n/a	c.724G > A	1/97 (1)	p.A242T, conserveda",123,51,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.D255D,"...	Chr9: 125,823,236	rs61734362	c.765C > T	1/97 (1)	p.D255D",125,58,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.P261P,"...Chr9: 125,823,254	rs1042486	c.783G > C	46/97 (45)	p.P261P",126,59,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.A339A,"...Exon 5	Chr9: 125,834,603	n/a	c.1017C > G	1/97 (1)	p.A339A",127,52,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.Ala242Thr,"...ed a heterozygous c.724G > A change, resulting in p.Ala242Thr. Though this is a conserved alanine re...",135,96,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.Asn125Ser,"...erozygous missense mutation in HESX1, c.374A > G (p.Asn125Ser). However, since this polymorphism has...",140,161,Am_J_Med_Genet_A_2010_Nov_11_152A(11)_2736-2742.txt
p.Ala172Phe,...al ReportsThe Fibroblast Growth Factor Receptor 2 p.Ala172Phe Mutation in Pfeiffer Syndrome—History ...,3,204,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...drome caused by a heterozygous missense mutation, p.Ala172Phe, located in the IgII domain of FGFR2. ...",7,835,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Pro252Arg,"...011]. Occasionally, a specific mutation in FGFR1, p.Pro252Arg can cause Pfeiffer syndrome—phenotypic...",14,295,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...cutive nucleotides (c.514_515delGCinsTT, encoding p.Ala172Phe) and was previously known only from Pf...",16,795,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...ere present in cis: c.514_515delGCinsTT, encoding p.Ala172Phe. This sequence change is identical to ...",33,429,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...regated with a 142 bp allele, suggesting that the p.Ala172Phe mutation had arisen independently in t...",37,675,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...ted British family, has also been implicated. The p.Ala172Phe mutation, involving a double nucleotid...",40,462,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,...e Pfeiffer syndrome phenotype associated with the p.Ala172Phe mutation is atypical in both its combi...,42,76,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...anomalies, these are a more severe feature of the p.Ala172Phe mutation than most other FGFR2-associa...",42,1762,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...ype (mild skull/severe limb) correlation with the p.Ala172Phe mutation, both within and across famil...",42,2474,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"...ons and direct receptor–receptor contacts. In the p.Ala172Phe mutation, substituting the small alani...",71,807,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.Ala172Phe,"... conclusion, Pfeiffer syndrome resulting from the p.Ala172Phe mutation is infrequent—only two famili...",75,53,Am_J_Med_Genet_A_2013_May_26_161(5)_1158-1163.txt
p.W299R,JC_0759	62	M	6/12	6/12	23.16	22.92	RGS9	p.W299R / p.R128X	MCW,93,41,Am_J_Ophthalmol_2015_Dec_160(6)_1269-1275_e1.txt
p.R128X,JC_0759	62	M	6/12	6/12	23.16	22.92	RGS9	p.W299R / p.R128X	MCW,93,51,Am_J_Ophthalmol_2015_Dec_160(6)_1269-1275_e1.txt
p.Ile442Met,"...nsin I complex, subunit G (NCAPG) gene encoding a p.Ile442Met variant is associated with an increase...",1143,89,Anim_Sci_J_2016_Feb_11_87(2)_159-167.txt
p.Arg628Pro,"...n, had a homozygous missense mutation, c.1883G>C (p.Arg628Pro) that occurred within the extracellula...",48,491,Ann_Dermatol_2015_Dec_7_27(6)_658-666.txt
p.Arg463Trp,"...as was the mutation in the fifth case, c.1387C>T (p.Arg463Trp)17. Clues to the molecular pathology o...",48,781,Ann_Dermatol_2015_Dec_7_27(6)_658-666.txt
p.Ala349Ser,"...strated the deleterious effects of the mutations (p.Ala349Ser, c.1538-1G>A, and p.Arg463Trp) on α3 i...",51,1428,Ann_Dermatol_2015_Dec_7_27(6)_658-666.txt
p.Arg463Trp,"...s of the mutations (p.Ala349Ser, c.1538-1G>A, and p.Arg463Trp) on α3 integrin structure, processing ...",51,1458,Ann_Dermatol_2015_Dec_7_27(6)_658-666.txt
p.Y279N,"...m. We described a novel homozygous, c. 835 T > A (p.Y279N) mutation in exon 6 in two patients",3,1589,Ann_Indian_Acad_Neurol_2013_Jul-Sep_16(3)_425-427.txt
p.Y279N,...evealed a homozygous novel mutation c. 835 T > A (p.Y279N) in exon 6,37,129,Ann_Indian_Acad_Neurol_2013_Jul-Sep_16(3)_425-427.txt
p.Arg438Cys,"...performed and the pathogenic mutation, c.1312C>T (p.Arg438Cys), was identified. Interestingly, this ...",3,1972,Ann_Lab_Med_2013_Mar_21_33(2)_150-152.txt
p.Arg438Cys,...that resulted in a change in the protein level of p.Arg438Cys (Fig. 2). Mutation analysis and clinic...,17,547,Ann_Lab_Med_2013_Mar_21_33(2)_150-152.txt
p.Glu255Lys,... a missense mutation [ABL1 NM_005157.4: c.763G>A (p.Glu255Lys)] was newly detected in the second eva...,15,772,Ann_Lab_Med_2015_Jan_8_35(1)_159-161.txt
p.Glu255Lys,...e was changed from G to A [NM_005157.4: c.763G>A (p.Glu255Lys)],25,501,Ann_Lab_Med_2015_Jan_8_35(1)_159-161.txt
p.G296S,...S    A novel mutation KCNQ4 pore-region mutation (p.G296S) causes deafness by impairing cell-surface...,150,98,Appl_Clin_Genet_2012_Oct_18_5_97-104.txt
p.Arg1256X,"...mutations, c.1153dupG (p.Val385fs) and c.3766C>T (p.Arg1256X), in EIF2AK4. Unaffected parents were h...",18,405,Appl_Clin_Genet_2015_Aug_7_8_181-188.txt
p.Arg1150X,"... (c.860-1G>A) and a nonsense mutation, c.3438C>T (p.Arg1150X). No mutations were identified in this ...",18,913,Appl_Clin_Genet_2015_Aug_7_8_181-188.txt
p.D630Y,"... GNA11, GNAQ, and SF3B1). The mutation (c.G1888T, p.D630Y) lies in the Y-domain of the highly conser...",41,346,Appl_Clin_Genet_2016_Sep_6_9_147-155.txt
p.D630Y,...tein is a downstream target of GNA11/GNAQ and the p.D630Y PLCB4 mutation was mutually exclusive with...,41,602,Appl_Clin_Genet_2016_Sep_6_9_147-155.txt
p.Asp411Cys,...n of this codon showed that in-vitro mutagenesis (p.Asp411Cys) resulting i,119,62,Arq_Bras_Cardiol_2015_Nov_105(5)_536-539.txt
p.His161Arg,...active Crohn's disease and analysis of the IL-17F p.His161Arg polymorphism in IBD Inflamm Bowel Dis ...,141,325,Arthritis_Res_Ther_2008_Apr_18_10(2)_206.txt
p.Gln4154Lys,"...ciation of the APOB gene polymorphism c.12669G>A, p.Gln4154Lys with the risk of CAD varies considera...",3,1299,Balkan_J_Med_Genet_2011_Dec_8_14(2)_35-40.txt
p.Gln4154Lys,"...ve studied the APOB gene polymorphism c.12669G>A, p.Gln4154Lys and its relationship with lipid, apoB...",3,1580,Balkan_J_Med_Genet_2011_Dec_8_14(2)_35-40.txt
p.Gln4154Lys,"...ion in linking APOB gene polymorphism (c.12669G>A,p.Gln4154Lys) with CAD risk in different populatio...",8,1395,Balkan_J_Med_Genet_2011_Dec_8_14(2)_35-40.txt
p.Gln4154Lys,"...he role of the APOB gene polymorphism (c.12669G>A,p.Gln4154Lys) was studied in native Indian Punjabi...",28,74,Balkan_J_Med_Genet_2011_Dec_8_14(2)_35-40.txt
p.Asp727Glu,"... MNG. We investigated the codon 727 polymorphism (p.Asp727Glu, p.D727E) of the human TSHR gene using...",3,1433,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...stigated the codon 727 polymorphism (p.Asp727Glu, p.D727E) of the human TSHR gene using the polymera...",3,1446,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...ers in exon 10 of the TSHR gene that contains the p.D727E polymorphism and digested by theNlaIII (Hi...,3,1835,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...e TSH (p = 0.047). These results suggest that the p.D727E polymorphism of the TSHR gene may not cont...,3,2354,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.Asp727Glu,... substitution of glutamic acid for aspartic acid (p.Asp727Glu; p.D727E) in the intracellular portion...,8,1212,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,... of glutamic acid for aspartic acid (p.Asp727Glu; p.D727E) in the intracellular portion of the recep...,8,1225,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...ith toxic or non toxic MNG, the expression of the p.D727E variant in eukaryotic cells resulting in a...",8,1351,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...type TSHR gene increased cAMP accumulation. Thus, p.D727E could induce growth and function of thyroc...",8,1578,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...s [1]. We have investigated the frequency of this p.D727E polymorphism in Turkish patients with MNG ...,8,1681,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...ion in exon 10 of the TSHR gene that contains the p.D727E polymorphism (rs1991517), as previously de...",17,263,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...th the non toxic MNG and control group, while the p.D727E polymorphism is significantly correlated w...",26,551,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"We screened the p.D727E polymorphism of the TSHR gene, a predispos...",29,17,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...ta did not show a direct relationship between the p.D727E polymorphism and non toxic MNG in our grou...,29,177,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...c MNG in our groups. Clearly, the presence of the p.D727E polymorphism in the TSHR gene is not suffi...",29,260,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,Gabriel et al.[1] indicated that a p.D727E polymorphism of the human TSHR gene was si...,31,36,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...at the presence of the heterozygous state for the p.D727E polymorphism of the TSHR gene was not sole...,31,363,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...al.[13] studied the frequency of the polymorphism p.D727E in a large group of patients with non auto...,33,192,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...sion, taking into consideration the fact that the p.D727E TSHR variant is frequently detected in the...",35,60,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...in our population. This is the first study of the p.D727E polymorphism in Turkish patients with MNG....,35,466,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,"...ish patients with MNG. According to our data, the p.D727E variant is frequently detected in the gene...",35,544,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,...igure 1 The PCR-based restriction analysis of the p.D727E polymorphisms of the TSHR gene shown on 2%...,37,52,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.D727E,Table 3 The distribution of the p.D727E genotypes and allelic frequencies of the T...,68,33,Balkan_J_Med_Genet_2012_Dec_2_15(2)_67-72.txt
p.G130V,...anze A.   New evidence for the correlation of the p.G130V mutation in the GJB2 gene and syndromic he...,163,178,Biochem_J_2010_Aug_1_429(Pt_3)_473-483.txt
p.Arg488Ter,"...cal case [chrX:47086497C>T, Q00536-2 (isoform 2): p.Arg488Ter] (http://genetics.emory.edu/egl/emvcla...",91,924,Biochem_J_2015_Aug_1_469(Pt_3)_409-420.txt
p.L849P,"...oint mutation Cav1.4 L860P [14,15] referred to as p.L849P in these publications and the truncation m...",33,78,Biochim_Biophys_Acta_2014_Aug_1838(8)_2053-2065.txt
p.R1816X,...tion mutation Cav1.4 R1827X ([15]; referred to as p.R1816X therein) were introduced into the Cav1.4 ...,33,172,Biochim_Biophys_Acta_2014_Aug_1838(8)_2053-2065.txt
p.R1816X,... mutation in C-terminus at position Arg1827 (also p.R1816X in [15]; Fig. 1a) was found in an 8-year ...,52,57,Biochim_Biophys_Acta_2014_Aug_1838(8)_2053-2065.txt
p.Leu849Pro,"...utation, where a proline residue replaced Leu860 (p.Leu849Pro in [14,15]). The L860P mutation is loc...",56,73,Biochim_Biophys_Acta_2014_Aug_1838(8)_2053-2065.txt
p.S34N,"...ported that local deficiency in hCAP-18/LL-37 and p.S34N mutation in CAMP gene, which is the gene en...",28,875,Biomed_Res_Int_2014_May_19_2014_420830.txt
p.S34N,...koğlu O  Berdeli A  Emingil G  Atilla G   A novel p.S34N mutation of CAMP gene in patients with peri...,188,57,Biomed_Res_Int_2014_May_19_2014_420830.txt
p.V600E, c.1799T>A	p.V600E	56 (29.9),189,12,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.K601E, c.1801A>G	p.K601E	11 (5.9),192,12,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.G12S, c.34G>A	p.G12S	1 (0.5),194,10,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61R, c.182A>G	p.Q61R	34 (18.2),196,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61K, c.181C>A	p.Q61K	5 (2.7),197,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61R, c.182A>G	p.Q61R	7 (3.7),199,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61K, c.181C>A	p.Q61K	6 (3.2),200,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61H, c.183G>T	p.Q61H	1 (0.5),201,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61R, c.182A>G	p.Q61R	8 (4.3),203,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61H, c.181C>A	p.Q61H	1 (0.5),204,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61K, c.180_181TC>AA	p.Q61K	1 (0.5),205,17,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.V600E, c.1799T>A	p.V600E	51,244,12,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.K601E, c.1801A>G	p.K601E	6,246,12,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.G12S, c.34G>A	p.G12S	1,248,10,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61R, c.182A>G	p.Q61R	29,250,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61K, c.181C>A	p.Q61K	7,251,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61R, c.182A>G	p.Q61R	4,253,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61K, c.181C>A	p.Q61K	3,254,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61R, c.182A>G	p.Q61R	2,256,11,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.Q61K, c.180_181TC>AA	p.Q61K,257,17,Biomed_Res_Int_2015_Jan_12_2015_697068.txt
p.R1441C,... K.  Rademakers R.  Theuns J.    Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene ...,127,63,Biomed_Res_Int_2015_Mar_2_2015_678701.txt
p.R196P,23	1	−	+ (76%)	Exon 6/p.R196P,58,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.R273H,24	2	+ (86%)	−	Exon 8/p.R273H,59,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.H178D,25	2	+ (80%)	−	Exon 5/p.H178D,60,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.R175H,26	2	+ (70%)	−	Exon 5/p.R175H,61,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.R273H,27	2	+ (94%)	−	Exon 8/p.R273H,62,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.R248E,28	2	+ (79%)	−	Exon 7/p.R248E,63,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.R249S,29	2	+ (6%)	−	Exon 7/p.R249S,64,22,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.P142R,30	2	+ (53%)	−	Exon 5/p.P142R and exon 6/m.P222 L,66,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.V272M,31	2	+ (91%)	−	Exon 8/p.V272M,67,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.Del264L,37	3	+ (17%)	−	Exon 8/p.Del264L,73,23,Blood_Cancer_J_2011_Feb_25_1(2)_e5.txt
p.G12V,...hybridization. A KRAS codon 12 mutation (c.35G>T; p.G12V) was detected in the pyloric gland adenoma ...,7,900,BMC_Cancer_2012_Dec_4_12_570.txt
p.G12V,"...ed a point mutation at exon 1, codon 12 (c.35G>T; p.G12V) and wildtype sequence at exon 2 in the pyl...",55,100,BMC_Cancer_2012_Dec_4_12_570.txt
p.G12R,"...in, serotonin, somatostatin, gastrin	KRAS exon 1 (p.G12R; c.34G>C)",83,172,BMC_Cancer_2012_Dec_4_12_570.txt
p.G12V,"...C1, p16), negative: MUC2, CD10, CDX2	KRAS exon 1 (p.G12V; c.35G>T); CGH: gains at 1q, 6p11p22, 7p, 1...",96,152,BMC_Cancer_2012_Dec_4_12_570.txt
p.G13D,...  Frattini M  Piessevaux H    Association of KRAS p.G13D mutation with outcome in patients with chem...,417,146,BMC_Cancer_2016_Aug_2_16_585.txt
p.Ala567Thr,c.1699G>A	p.Ala567Thr	rs1803274,41,12,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Asp2213Asn,c.6637G>A	p.Asp2213Asn	rs529038,44,12,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Pro200Leu,c.599C>T	p.Pro200Leu	rs1050450,50,11,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Arg176Cys,c.526C>T	p.Arg176Cys	rs7412,56,11,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Cys130Arg,c.388 T>C	p.Cys130Arg	rs429358,59,12,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Asp432Glu,c.1296 T>G	p.Asp432Glu	rs7041,62,13,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Thr436Lys,c.1307C>A	p.Thr436Lys	rs4588,65,12,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Met1Thr,c.2 T>C	p.Met1Thr	rs2228570,68,10,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Ala567Thr,"...ly the rs1803274 polymorphism of BCHE (c.1699G>A, p.Ala567Thr) was associated with an increased risk...",250,189,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.Ala567Thr,"Our results show that the rs1803274 (1699G>A, p.Ala567Thr) polymorphism of BCHE was also signifi...",265,47,BMC_Cardiovasc_Disord_2015_Oct_24_15_135.txt
p.T972M,"...n exon 7 of the CaSR gene was found, predicting a p.T972M amino acid substitution in cytoplasmic tai...",43,551,BMC_Endocr_Disord_2014_Oct_7_14_81.txt
p.T972M,"...ction was carried out with the following primers (p.T972M, For: 5’ -catctttggcagcggcaTggtcaccttctcac...",85,183,BMC_Endocr_Disord_2014_Oct_7_14_81.txt
p.T972M,"... novel variant of the exon 7, namely c.2915C > T, p.T972M (Figure 1) in heterozygosity. This variant...",100,512,BMC_Endocr_Disord_2014_Oct_7_14_81.txt
p.R605Q,"..., respectively. Two missense mutations (p.M1? and p.R605Q) of unknown functional significance were i...",7,259,BMC_Gastroenterol_2012_Oct_15_12_141.txt
p.L398L,Exon 12	c.1194A>G	NA	p.L398L	benign	AA 9/39; AG 12/39; GG 18/39 (AF:A 0...,36,22,BMC_Gastroenterol_2012_Oct_15_12_141.txt
p.R605Q,Exon 17	c.1814G>A	NA	p.R605Q	unknown	1/39 (het: Pt-7) (0.013)	0/100	pre...,37,22,BMC_Gastroenterol_2012_Oct_15_12_141.txt
p.R605Q,...f cDNA from an 851del4-homozygous patient and the p.R605Q-heterozygous individual revealed correct s...,47,63,BMC_Gastroenterol_2012_Oct_15_12_141.txt
p.R605Q,"... to have 851del4, IVS16ins3kb, 1638ins23, and the p.R605Q variant (creating a BsrDI restriction site...",47,242,BMC_Gastroenterol_2012_Oct_15_12_141.txt
p.R605Q,"...n AGC2 function, it remains to be elucidated. The p.R605Q mutation occurs at a conserved amino acid ...",112,450,BMC_Gastroenterol_2012_Oct_15_12_141.txt
p.D19H,Gallstone disease is associated with p.D19H of ABCG8 as well as alterations of choleste...,4,38,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,...ed from blood leukocytes. Genotype frequencies of p.D19H were established using MALDI-TOF mass spect...,7,494,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,...ption was about 24% lower in individuals carrying p.D19H compared to wild type (Psitosterol = 0.0080...,10,495,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"... Moreover, irrespective of phenotype, carriers of p.D19H displayed a significant lower absorption th...",10,620,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,... in gallstone carriers and controls regardless of p.D19H presence,10,1039,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,Both gallstone disease and p.D19H of ABCG8 are associated with diminished cho...,13,28,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"... with diminished cholesterol absorption. However, p.D19H is not responsible for the differences in s...",13,108,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"...verweight simultaneous carriers of gallstones and p.D19H displayed a higher OR (OR = 3.2, P = 0.0430...",142,881,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,...t. (GG) = wild type individual; (Gc) = carrier of p.D19H; (GG) = 93 and (Gc) = 25. * Psitosterol = 0...,158,546,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"..., P = 0.0347 and wild type controls to cases with p.D19H 37%, P = 0.0030). Regarding the cholesterol...",160,775,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"...vidual): C = 75, GS = 14; Gc genotype (carrier of p.D19H): C = 18, GS = 11",162,680,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,...s. (GG) = wild type individual; (Gc) = carrier of p.D19H. Controls: (GG) = 80 and (Gc) = 15; gallsto...,166,499,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"...ividuals and gallstone carriers, with and without p.D19H. Protein content was determined by densitom...",166,733,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.D19H,"...erol gallstones [27,29]. In our study carriers of p.D19H were characterised by significantly reduced...",181,503,BMC_Gastroenterol_2013_Feb_13_13_30.txt
p.Trp82Arg,...of nine affected members of a new family with the p.Trp82Arg ALys variant were recorded. All affecte...,7,222,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,...amyloid deposits in all cases and all carried the p.Trp82Arg ALys variant at a heterozygous state,7,633,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,Hereditary amyloidosis associated with the p.Trp82Arg lysozyme variant in this new family is ...,10,44,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,...y. We report here a new large family in which the p.Trp82Arg variant (this nomenclature includes the...,16,1003,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,"...iety guidelines, http://www.hgvs.org/mutnom// and p.Trp82Arg corresponds to the previous Trp64Arg va...",16,1172,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,"...ge of the amino acid from tryptophan to arginine (p.Trp82Arg in the new nomenclature, corresponds to...",25,399,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,"... the mature protein from tryptophane to arginine. p.Trp82Arg in the new nomenclature, wich was previ...",40,429,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,...new family of hereditary ALys associated with the p.Trp82Arg variant is of particular interest becau...,66,56,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.Trp82Arg,The families with the p.Trp82Arg variant already reported are either fro...,76,23,BMC_Gastroenterol_2014_Sep_13_14_159.txt
p.R163Q,"...etween Asia and all other populations, due to the p.R163Q (c.488 G>A) polymorphism. The least amount...",9,397,BMC_Genet_2008_Apr_10_9_31.txt
p.P18A,p.P18A	c.52 C>G	0	0	0	0	0.08	0	0	0,40,1,BMC_Genet_2008_Apr_10_9_31.txt
p.C35Y,p.C35Y	c.104 G>A	0	0	0	0	0	0.12	0	0,41,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V38M,p.V38M	c.112 G>A	0	0	0	0	0	0.06	0	0,42,1,BMC_Genet_2008_Apr_10_9_31.txt
p.L44V,p.L44V	c.130 C>G	0	0	0	0	0	0.06	0	0,43,1,BMC_Genet_2008_Apr_10_9_31.txt
p.F45L,p.F45L	c.133 T>C	0	0	0	0	0	0.24	0	0,44,1,BMC_Genet_2008_Apr_10_9_31.txt
p.S47I,p.S47I	c.140 G>T	0	0.43	0	0	0	0	0	0,45,1,BMC_Genet_2008_Apr_10_9_31.txt
p.L50L,p.L50L	c.150 G>A	0	1.28	0	0	0	0	0	0,46,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V60L,p.V60L	c.178 G>T	0.10	0	0	0	10.69	15.75	13.21	0,47,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R67Q,p.R67Q	c.200 G>A	0	0	1.17	0	0	0.06	0	0,48,1,BMC_Genet_2008_Apr_10_9_31.txt
p.A81P,p.A81P	c.241 G>C	0	0	0	0	0.08	0	0	0,49,1,BMC_Genet_2008_Apr_10_9_31.txt
p.S83P,p.S83P	c.247 T>C	0	0	0	0	0.15	0.12	0.19	0,50,1,BMC_Genet_2008_Apr_10_9_31.txt
p.S83L,p.S83L	c.248 C>T	0	0	0	0	0	0.06	0	0,51,1,BMC_Genet_2008_Apr_10_9_31.txt
p.D84E,p.D84E	c.252 C>A	0	0	0	0	1.00	0.12	1.51	0,52,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V92M,p.V92M	c.274 G>A	0.07	0	13.41	0.94	8.00	3.70	9.06	...,53,1,BMC_Genet_2008_Apr_10_9_31.txt
p.T95M,p.T95M	c.284 C>T	0	0	0	0	0.08	0.12	0	0,54,1,BMC_Genet_2008_Apr_10_9_31.txt
p.L99I,p.L99I	c.295 C>A	0	0.43	0	0	0	0	0	0,55,1,BMC_Genet_2008_Apr_10_9_31.txt
p.A103A,p.A103A	c.309 C>T	0	0.43	0	0	0	0	0	0,56,1,BMC_Genet_2008_Apr_10_9_31.txt
p.L106Q,p.L106Q	c.317 T>A	0	0	0	0	0	0.06	0	0,57,1,BMC_Genet_2008_Apr_10_9_31.txt
p.A111V,p.A111V	c.332 C>T	0	0	0	0	0	0.18	0	0,59,1,BMC_Genet_2008_Apr_10_9_31.txt
p.I120T,p.I120T	c.359 T>C	0	0	1.75	0	0	0.06	0	0,60,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V122M,p.V122M	c.364 G>A	0	0	0	0	0	0.24	0	0,61,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V122V,p.V122V	c.366 G>C	0	0	0	0	0	0.12	0	0,62,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R142H,p.R142H	c.425 G>A	0.01	0	0	0	0.62	1.31	0.75	0,63,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R151C,p.R151C	c. 451 C>T	0.03	0	0	0	5.62	3.16	6.42	0,64,1,BMC_Genet_2008_Apr_10_9_31.txt
p.Y152X,p.Y152X	c.456 C>A	0	0	0	0	0	0.06	0	0,65,1,BMC_Genet_2008_Apr_10_9_31.txt
p.I155T,p.I155T	c.464 T>C	0	0	0	0	0.23	0.48	1.51	0,66,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R160W,p.R160W	c.478 C>T	0.04	0	0	0	8.31	1.85	7.17	0,67,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R160Q,p.R160Q	c.479 G>A	0	0	0	0	0	0.06	0	5,68,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R163Q,p.R163Q	c.488 G>A	0.14	0	75.51	4.72	4.62	1.61	4.15...,69,1,BMC_Genet_2008_Apr_10_9_31.txt
p.A166A,p.A166A	c.498 G>A	0	0	0	0	0	0	0	11.25,70,1,BMC_Genet_2008_Apr_10_9_31.txt
p.I168I,p.I168I	c.504 C>T	0	0.43	0	0	0	0	0	0,71,1,BMC_Genet_2008_Apr_10_9_31.txt
p.A171D,p.A171D	c.512 C>A	0	0	0	0	0	0.06	0	0,72,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V174I,p.V174I	c.520 G>A	0	0	0	0	0.08	0	0	0,73,1,BMC_Genet_2008_Apr_10_9_31.txt
p.Y182Y,p.Y182Y	c.546 C>T	0	0	0	0	0	0	0.19	0,74,1,BMC_Genet_2008_Apr_10_9_31.txt
p.F196L,p.F196L	c.586 T>C	0	2.14	0.15	0	0.08	0	0	0,75,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R213W,p.R213W	c.637 C>T	0	0	0	0	0	0.06	0	0,76,1,BMC_Genet_2008_Apr_10_9_31.txt
p.G220G,p.G220G	c.660 C>T	0	0	0	0	0	0.06	0	0,77,1,BMC_Genet_2008_Apr_10_9_31.txt
p.Q228Q,p.Q228Q	c.684 G>A	0	0	0	0	0	0.12	0	0,78,1,BMC_Genet_2008_Apr_10_9_31.txt
p.P230L,p.P230L	c.689 C>T	0	0	0	0	0.31	0	0	0,79,1,BMC_Genet_2008_Apr_10_9_31.txt
p.P230P,p.P230P	c.690 G>A	0	0	0	0	0.08	0	0	0,80,1,BMC_Genet_2008_Apr_10_9_31.txt
p.Q233Q,p.Q233Q	c.699 G>A	0	0	0	0	0	0.36	0.19	0,81,1,BMC_Genet_2008_Apr_10_9_31.txt
p.A240A,p.A240A	c.720 T>C	0	0	0	0	0	0	0.19	0,82,1,BMC_Genet_2008_Apr_10_9_31.txt
p.T242T,p.T242T	c.726 C>T	0	0	0	0	0	0.12	0	0,83,1,BMC_Genet_2008_Apr_10_9_31.txt
p.G248V,p.G248V	c.743 G>T	0	0	0	0	0	0.06	0	0,84,1,BMC_Genet_2008_Apr_10_9_31.txt
p.H260P,p.H260P	c.779 A>C	0	0	0	0	0.23	0	0	0,85,1,BMC_Genet_2008_Apr_10_9_31.txt
p.I264I,p.I264I	c.792 C>T	0	0	0	0	0.15	0	0	0,86,1,BMC_Genet_2008_Apr_10_9_31.txt
p.V265V,p.V265V	c.795 C>G	0	1.28	0	0	0	0	0	0,87,1,BMC_Genet_2008_Apr_10_9_31.txt
p.C273C,p.C273C	c.819 C>T	0	0.43	0	0	0	0	0	0,88,1,BMC_Genet_2008_Apr_10_9_31.txt
p.K278E,p.K278E	c.832 A>G	0	0	0	0	0.23	0.24	0	0,89,1,BMC_Genet_2008_Apr_10_9_31.txt
p.N279K,p.N279K	c.837 C>A	0	0	0	0	0	0.06	0	0,90,1,BMC_Genet_2008_Apr_10_9_31.txt
p.D294H,p.D294H	c.880 G>C	0.01	0	0	0	1	1.43	2.45	0,91,1,BMC_Genet_2008_Apr_10_9_31.txt
p.F300F,p.F300F	c.900 C>T	0	2.99	0	0	0	0	0	0,92,1,BMC_Genet_2008_Apr_10_9_31.txt
p.T308M,p.T308M	c.923 C>T	0	0	0	0	0	0.06	0	0,93,1,BMC_Genet_2008_Apr_10_9_31.txt
p.T314T,p.T314T	c.942 A>G	0.09	44.44	13.27	13.21	7.69	2.33...,94,1,BMC_Genet_2008_Apr_10_9_31.txt
p.R151C,"...the allele frequency of the T allele of c.451C>T, p.R151C, was 1.9% in Greece but 10.2% in Britain/I...",171,673,BMC_Genet_2008_Apr_10_9_31.txt
p.L502V, 	 	c.1504C > G (p.L502V)	9193	31	60	38	1.5	58.57	37.59	2.3	0.00	0....,54,18,BMC_Genet_2013_Feb_19_14_6.txt
p.R124W, 	 	c.370C > T (p.R124W)	18217	32.3	58	39	1.77	58.36	0.48	39.35	0....,57,17,BMC_Genet_2013_Feb_19_14_6.txt
p.V320A,CBS	NM_000071.2	c.959 T > C (p.V320A)	8715	24.4	7	91	0.48	90.82	1.63	7.05	0.00	...,62,30,BMC_Genet_2013_Feb_19_14_6.txt
p.M470V,CFTR	NM_000492.3	c.1408 G > A (p.M470V)	9356	30.4	60	38	38.44	0.46	60.04	0.99	0.0...,64,32,BMC_Genet_2013_Feb_19_14_6.txt
p.D882G,DMD	NM_004006.2	c.2645A > G (p.D882G)	2974	19.6	5	93	4.98	0.87	92.67	1.48	0	0,67,30,BMC_Genet_2013_Feb_19_14_6.txt
p.R1745H, 	 	c.5234 G > A (p.R1745H)	4289	23.4	4	93	93.38	1.19	4.13	1.31	0	0,68,19,BMC_Genet_2013_Feb_19_14_6.txt
p.R2937Q, 	 	c.8810 G > A (p.R2937Q)	3235	20.1	4	94	94.03	1.08	4.33	0.56	0	0,71,19,BMC_Genet_2013_Feb_19_14_6.txt
p.H199R, 	 	c.596A > G (p.H199R)	11616	29.2	9	86	9.13	2.95	85.73	2.18	0.00...,74,17,BMC_Genet_2013_Feb_19_14_6.txt
p.R223H, 	 	c.668 G > A (p.R223H)	10344	31.4	5	93	92.62	1.14	4.89	1.31	0.00...,75,18,BMC_Genet_2013_Feb_19_14_6.txt
p.S601L, 	 	c.1802C > T (p.S601L)	6027	21.4	59	34	2.17	59.25	4.35	34.23	0.0...,85,18,BMC_Genet_2013_Feb_19_14_6.txt
p.V780I, 	 	c.2338 G > A (p.V780I)	8957	10.2	11	83	82.93	3.74	10.73	2.57	0.0...,90,19,BMC_Genet_2013_Feb_19_14_6.txt
p.R184C, 	 	c.550C > T (p.R184C)	9215	19.6	39	54	2.59	38.77	4.75	53.88	0	0...,94,17,BMC_Genet_2013_Feb_19_14_6.txt
p.D248N, 	 	c.742 G > A (p.D248N)	15664	32.8	62	35	35.28	0.5	61.78	2.43	0	0...,96,18,BMC_Genet_2013_Feb_19_14_6.txt
p.T529M, 	 	c.1586C > T (p.T529M)	15938	25.7	16	78	2.41	16.18	3.38	78.02	0	...,98,18,BMC_Genet_2013_Feb_19_14_6.txt
p.T641A, 	 	c.1921A > G (p.T641A)	20556	23.6	2	97	2.13	0.88	96.5	0.49	0	0.0...,103,18,BMC_Genet_2013_Feb_19_14_6.txt
p.I562T, 	 	c.1685 T > C (p.I562T)	30664	31.2	58	39	1.99	38.95	1.47	57.58	0	...,109,19,BMC_Genet_2013_Feb_19_14_6.txt
p.T641A, 	 	c.1921A > G (p.T641A)	15648	23	2	96	2.19	1.04	96.42	0.35	0	0.01...,112,18,BMC_Genet_2013_Feb_19_14_6.txt
p.R259Q,GALT	NM_000155.2	c.776 G > A (p.R259Q)	27403	31.3	62	32	31.51	2.92	62.00	3.55	0....,113,31,BMC_Genet_2013_Feb_19_14_6.txt
p.D273H, 	 	c.817 G > C (p.D273H)	27824	32.3	61	38	0.68	37.71	60.85	0.73	0....,114,18,BMC_Genet_2013_Feb_19_14_6.txt
p.N409S, 	 	c.1226 A > G (p.N409S)	2864	20.4	62	36	61.91	0.8	36.03	1.26	0	0,116,19,BMC_Genet_2013_Feb_19_14_6.txt
p.L483P, 	 	c.1448 T > C (p.L483P)	3331	26.4	60	38	0.99	38.04	0.9	60.07	0	0,117,19,BMC_Genet_2013_Feb_19_14_6.txt
p.A495P, 	 	c.1483 G > C (p.A495P)	2569	16.3	53	44	1.01	44.45	53.41	1.05	0	0...,118,19,BMC_Genet_2013_Feb_19_14_6.txt
p.N409S, 	 	c.1226 A > G (p.N409S)	3813	22.9	71	23	70.52	1.1	26.86	1.52	0	0,121,19,BMC_Genet_2013_Feb_19_14_6.txt
p.L62S,HEXB	NM_000521.3	c.185 T > C (p.L62S)	21320	33.2	8	86	3.63	86.44	2.33	7.59	0.00	...,125,31,BMC_Genet_2013_Feb_19_14_6.txt
p.K121R, 	 	c.362A > G (p.K121R)	14201	27.9	66	32	65.63	1.11	31.86	1.39	0....,126,17,BMC_Genet_2013_Feb_19_14_6.txt
p.R505W, 	 	c.1513C > T (p.R505W)	8306	30.9	62	37	0.52	61.77	0.92	36.78	0.0...,129,18,BMC_Genet_2013_Feb_19_14_6.txt
p.G549R, 	 	c.1645 G > A (p.G549R)	33259	34.6	84	15	15.46	0.47	83.69	0.36	0....,131,19,BMC_Genet_2013_Feb_19_14_6.txt
p.H33Q,IDUA	NM_000203.3	c.99 T > G / p.H33Q	34	10.2	6	91	2.94	0.00	91.18	5.88	0.00	0.00...,132,31,BMC_Genet_2013_Feb_19_14_6.txt
p.Q70X, 	 	c.208C > T (p.Q70X)	4106	9.4	49	46	2.65	49.05	1.90	46.40	0.00	...,133,17,BMC_Genet_2013_Feb_19_14_6.txt
p.R105Q, 	 	c.314 G > A (p.R105Q)	10809	28.7	62	34	33.71	1.86	62.39	2.01	0....,135,18,BMC_Genet_2013_Feb_19_14_6.txt
p.A361T, 	 	c.1081 G > A (p.A361T)	9486	26.7	60	38	37.50	1.18	59.99	1.33	0.0...,142,19,BMC_Genet_2013_Feb_19_14_6.txt
p.T388T, 	 	c.1164 G > C (p.T388T)	3080	23.1	65	31	2.05	31.30	65.16	1.49	0.0...,143,19,BMC_Genet_2013_Feb_19_14_6.txt
p.W402X, 	 	c.1205 G > A (p.W402X)	2679	23.2	62	32	31.88	5.30	61.55	1.27	0.0...,144,19,BMC_Genet_2013_Feb_19_14_6.txt
p.S92P, 	 	c.274 T > C (p.S92P)	2505	11.9	14	75	4.79	74.61	6.43	14.17	0	0,149,18,BMC_Genet_2013_Feb_19_14_6.txt
p.S246S, 	 	c.738C > T (p.S246S)	10356	27.9	76	24	0.3	75.69	0.32	23.68	0	0...,150,17,BMC_Genet_2013_Feb_19_14_6.txt
p.E267D, 	 	c.801 G > C (p.E267D)	5788	28.6	64	34	0.57	34.45	63.99	0.93	0	0...,151,18,BMC_Genet_2013_Feb_19_14_6.txt
p.R1005Q, 	 	c.3014 G > A (p.R1005Q)	3027	27	50	48	47.9	1.06	50.21	0.83	0	0,155,19,BMC_Genet_2013_Feb_19_14_6.txt
p.L1043L, 	 	c.3127 T > C (p.L1043L)	13424	30.6	5	94	0.77	93.66	0.99	4.53	0	0...,156,19,BMC_Genet_2013_Feb_19_14_6.txt
p.S298P, 	 	c.892 T > C (p.S298P)	12564	31.7	60	38	0.93	37.61	1.13	60.31	0	...,164,18,BMC_Genet_2013_Feb_19_14_6.txt
p.R456H, 	 	c.1367 G > A (p.R456H)	8525	29.5	61	36	36.29	1.69	60.75	1.23	0	0...,165,19,BMC_Genet_2013_Feb_19_14_6.txt
p.V36A, 	 	c.107 T > C (p.V36A)	 	 	 	 	 	 	 	 	 	 ,167,18,BMC_Genet_2013_Feb_19_14_6.txt
p.R695X,ZEB2	NM_014795.3	c.2083C > T (p.R695X)	20800	24.9	75	24	0.51	75.22	0.4	23.88	0	0...,169,31,BMC_Genet_2013_Feb_19_14_6.txt
p.L502V,"...e nucleotide changes, such as ACADVL c.1504C > G (p.L502V), but also small deletions and insertion e...",237,941,BMC_Genet_2013_Feb_19_14_6.txt
p.L502V,...the SOLiD and Sanger data for ACADVL c.1504C > G (p.L502V) mutation. Panes 1B & 2B represent SOLiD a...,241,151,BMC_Genet_2013_Feb_19_14_6.txt
p.L502V,"...les we ran, there is a heterozygous c.1504 C > G (p.L502V) missense mutation in the ACADVL gene. Thi...",310,156,BMC_Genet_2013_Feb_19_14_6.txt
p.L99P,"...gh differentiation, (ii) the fixation of the MC1R p.L99P mutation in (old and new) BBC, BBM and HF, ...",118,724,BMC_Genomics_2014_Sep_17_15(1)_796.txt
p.L99P,"...RfsX13 mutation in (old and new) BBC and the MC1R p.L99P mutation in (old and new) BBC, BBM and HF i...",118,1235,BMC_Genomics_2014_Sep_17_15(1)_796.txt
p.P19S,"...se variants are a missense mutation (rs384285149, p.P19S, Chr1:97,309,054 bp) in a highly conserved ...",101,1311,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.P19S,The p.P19S (rs384285149) variant in EIF5A2 is predicte...,103,5,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.P19S,... retardation and a reduced lifespan in mice [17]. p.P19S is therefore a plausible candidate mutation...,103,277,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.P19S,... Sanger sequencing confirmed homozygosity for the p.P19S variant in EIF5A2 and for the p.L258fs16 va...,119,379,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.W317R,"...ing variant (rs110793536) is a missense mutation (p.W317R) in SUGT1 encoding SGT1, suppressor of G2 ...",130,58,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.W317R,...early embryonic lethality in eukaryotes [24]. The p.W317R-variant is predicted to be highly damaging...,130,354,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.W317R,...he SGT1 protein sequence. The red arrow indicates p.W317R. Protein sequences were obtained from NCBI...,130,719,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.V327I,"... in LOC783918 (rs384792959, Chr10: 26,948,606 bp, p.V327I). Thirty-eight (out of 263) sequenced anim...",141,828,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.P19S,...n initiation factor 5A-2. Red color indicates the p.P19S-variant (rs384285149). Protein sequences we...,208,183,BMC_Genomics_2015_Apr_18_16(1)_312.txt
p.R961W,"...factor receptor (EGFR) inhibitors; however, a KDR p.R961W c.2881C>T mutation was noted as a variant ...",9,1242,Cureus_8(2)_e478.txt
p.R961W,"...actor receptor (EGFR) inhibitors, however the KDR p.R961W c.2881C>T mutation that was noted as a var...",26,712,Cureus_8(2)_e478.txt
p.R961W,...dictive biomarker of response to regorafenib. KDR p.R961W c.2881C>T mutation has been reported twice...,50,1091,Cureus_8(2)_e478.txt
p.Gln27Glu,...valuated the potential relevance of the c.79 C>G (p.Gln27Glu) polymorphism of this receptor gene for...,9,77,BMC_Med_Genet_2006_Mar_30_7_31.txt
p.Gln27Glu,The genotyping for the c.79 C>G (p.Gln27Glu) polymorphism of β2-AR was determined b...,27,34,BMC_Med_Genet_2006_Mar_30_7_31.txt
p.G1706A,"...[p.Q23fs], c.330A > G, [p.64-71del], c.5236G > A [p.G1706A], c.5242C > A [p.A1708E], c.589-590delCT ...",20,184,BMC_Med_Genet_2007_Jun_29_8_40.txt
p.A1708E,"...p.64-71del], c.5236G > A [p.G1706A], c.5242C > A [p.A1708E], c.589-590delCT [p.S157X]; numbered Gene...",20,208,BMC_Med_Genet_2007_Jun_29_8_40.txt
p.S157X,"....G1706A], c.5242C > A [p.A1708E], c.589-590delCT [p.S157X]; numbered GeneBank U14680) account for 46...",20,235,BMC_Med_Genet_2007_Jun_29_8_40.txt
p.S157X,BRCA1 c.589-590delCT (p.S157X)	F ctcttcaggaggaaaagcac,40,23,BMC_Med_Genet_2007_Jun_29_8_40.txt
p.G1706A,BRCA1 c.5236 G > C (p.G1706A,42,21,BMC_Med_Genet_2007_Jun_29_8_40.txt
p.A1708E,BRCA1 c.5242 C > A (p.A1708E)	F ggacagcacttcctgatttt,43,21,BMC_Med_Genet_2007_Jun_29_8_40.txt
p.E34V,"...: c.101A>T, c.995G>C and c.670 T>G that result in p.E34V, p.G332A and W224G aminoacid substitutions ...",12,885,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.G332A,"...>T, c.995G>C and c.670 T>G that result in p.E34V, p.G332A and W224G aminoacid substitutions in exons...",12,893,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.G232R,...). One reported mutation was a missense mutation (p.G232R) and 2 were frameshift mutations: c.1082in...,12,1417,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,V	P	F	26	1.3	1.6	149	10.40	2411	+/-	c.101A>T/p.E34V,56,46,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,Si	F	31	1.2	2.1	539	6.00	1208	+/-	c.101A>T/p.E34V,57,45,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,VI	P	F	16	8.0	18.5	2619	10.12	ND	-/+	c.101A>T/p.E34V,58,47,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224R,VIII	P	F	40	2.4	4.2	874	5.50	1030	+/+	c.670T>G/p.W224R,67,48,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224R,D	F	15	0.9	1.4	34	1.28 (619)	ND	-/-	c.670T>G/p.W224R,69,47,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224R,A	F	45	2.5	2.3	450	11.77	893	+/+	c.670T>G/p.W224R,70,44,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.R168H,XXIII	P	F	24	6.4	8.2	1108	7.10	1529	+/+	c.503G>A/p.R168H,109,50,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.R168H,So	M	18	1.1	1.2	35	1.15 (619)	ND	-/-	c.503G>A/p.R168H,110,48,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.R168H,So	M	19	0.9	0.6	86	120	ND	-/-	c.503G>A/p.R168H,112,41,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.R168H,Si	F	35	ND	ND	ND	3.15	1281	+/-	c.503G>A/p.R168H,113,42,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.L178V,XXV	P	F	27	3.1	4.0	870	5.40	1592	+/-	c.532T>G/p.L178V,117,47,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.H106P,XXVI	P	F	39	4.4	6.2	307	5.33	1214	+/-	c.317A>C/p.H106P,118,48,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,V	P	18.48	55.58	c.101A>T/p.E34V,197,26,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224R,VIII	P	16.95	50.98	c.670T>G/p.W224R,201,29,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224R,D	18.12	54.19	c.670T>G/p.W224R,202,25,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,...tamic acid residue to a valine residue in exon 3 (p.E34V). The other was a G to C substitution at nu...,209,303,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.G332A,... glycine residue to a alanine residue in exon 10 (p.G332A). The last one was a T to G change at nucl...,209,512,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224G,"...eading to a tryptophan to a glycine substitution (p.W224G) (Proband VIII, Figure 7). These mutations...",209,644,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,...ity seems to be unprobable in these cases. In the p.E34V and p.W224G mutations the glutamic acid and...,240,640,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224G,...o be unprobable in these cases. In the p.E34V and p.W224G mutations the glutamic acid and the trypto...,240,651,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.G332A,"...dicted for human PPOX [50] In the other case, the p.G332A mutation, although the glycine residue is ...",240,815,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E34V,"...ment of eukaryotic PPOXs, revealed that mutations p.E34V and p.G332A affect residues that are conser...",242,103,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.G332A,"...aryotic PPOXs, revealed that mutations p.E34V and p.G332A affect residues that are conserved in mito...",242,114,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224G,"The last missense mutation, p.W224G affects a residue which is absent in the c...",244,29,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224X,...other two already described mutations causing VP: p.W224X [37] and p.W224R [39]. Recently was also s...,244,359,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.W224R,... described mutations causing VP: p.W224X [37] and p.W224R [39]. Recently was also suggested that thi...,244,376,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.G232R,"...ons were also found. One was a missense mutation, p.G232R [34,35]. The other 2 reported mutations we...",250,81,BMC_Med_Genet_2008_Jun_20_9_54.txt
p.E320Q,"...3. A pathogenic homozygous mutation (c.958G > C, [p.E320Q]) in SLC19A3 was identified in all four pa...",10,201,BMC_Med_Genet_2010_Dec_22_11_171.txt
p.E320Q,"...we identified a homozygous mutation (c.958G > C, [p.E320Q]) in exon 3 of SLC19A3 in all patients, wh...",97,93,BMC_Med_Genet_2010_Dec_22_11_171.txt
p.E320Q,"...racterization of a disease mutation (c.958G > C, [p.E320Q]). (A) The sequence analyses showed a G to...",99,82,BMC_Med_Genet_2010_Dec_22_11_171.txt
p.E320Q,"...mic acid at codon 320 for glutamine (c.958G > C, [p.E320Q]), indicated by an arrow. (B) RsaI (GTAC)-...",99,283,BMC_Med_Genet_2010_Dec_22_11_171.txt
p.E320Q,"... were caused by homozygous mutation (c.958G > C, [p.E320Q]) in SLC19A3. Our cases broaden the phenot...",114,330,BMC_Med_Genet_2010_Dec_22_11_171.txt
p.D398E,"...mination codon at position 1000; (c) c.1194T > A (p.D398E), the consequence of a transversion from T...",35,612,BMC_Med_Genet_2010_May_26_11_79.txt
p.E594K,"...partate to glutamate in exon 13; (d) c.1780G > A (p.E594K), a transition from G to A at nucleotide 1...",35,784,BMC_Med_Genet_2010_May_26_11_79.txt
p.E594K,16	c.1780 G > A	p.E594K	Missense	0501768	12	0/184,42,17,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,40	c.4819C > T	p.R1607W	Missense	0400695	1	0/184,45,16,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,"...e c.2975_2978delAG (p.Q994VfsX6) and c.4819C > T (p.R1607W), inherited from the mother and father re...",50,209,BMC_Med_Genet_2010_May_26_11_79.txt
p.D398E,"... chromatograms of pathogenic variants c.1194T > A/p.D398E, c.1740delC/p.s581PfsX40 and c.1780G>A/p.E...",52,143,BMC_Med_Genet_2010_May_26_11_79.txt
p.E594K,"... A/p.D398E, c.1740delC/p.s581PfsX40 and c.1780G>A/p.E594K. Two columns are sequencing chromatograms ...",52,190,BMC_Med_Genet_2010_May_26_11_79.txt
p.R49W,"...fied, including 4 missense mutations: c.145C > T (p.R49W), c.157G > A (p.A53T), c.158C > T (p.A53V) ...",54,113,BMC_Med_Genet_2010_May_26_11_79.txt
p.A53T,"...sense mutations: c.145C > T (p.R49W), c.157G > A (p.A53T), c.158C > T (p.A53V) and c.244C > T (p.R82...",54,134,BMC_Med_Genet_2010_May_26_11_79.txt
p.A53V,"...5C > T (p.R49W), c.157G > A (p.A53T), c.158C > T (p.A53V) and c.244C > T (p.R82C). Some of these pol...",54,155,BMC_Med_Genet_2010_May_26_11_79.txt
p.R82C,"...> A (p.A53T), c.158C > T (p.A53V) and c.244C > T (p.R82C). Some of these polymorphisms have been pre...",54,179,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,"... c.2975_2978delAG (p.Q994VfsX6), and c.4819C > T (p.R1607W). The frameshift mutation (c.2975_2978del...",69,132,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,...f c.2975_2978delAG (p.Q994VfsX6) and c.4819C > T (p.R1607W) were not found in our control group,69,445,BMC_Med_Genet_2010_May_26_11_79.txt
p.I515T,"...sponsible heterozygous mutation of the OTOF gene, p.I515T, was first found in two affected children ...",76,378,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,"...in function[8]. The paternally inherited mutation p.R1607W is a missense mutation, and p.R1607W was ...",76,1082,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,"...ted mutation p.R1607W is a missense mutation, and p.R1607W was the consequence of replacement of an ...",76,1119,BMC_Med_Genet_2010_May_26_11_79.txt
p.R1607W,...: c.2975_2978delAG (p.Q994VfsX6) and c.4819C > T (p.R1607W). The special mutation spectra of the OTO...,81,389,BMC_Med_Genet_2010_May_26_11_79.txt
p.G908R,"...ning 2 gene (NOD2, also known as CARD15), namely, p.G908R, p.R702W, and p.L1007fs [12-14]. These thr...",22,200,BMC_Med_Genet_2011_May_6_12_63.txt
p.R702W,"...ne (NOD2, also known as CARD15), namely, p.G908R, p.R702W, and p.L1007fs [12-14]. These three varian...",22,209,BMC_Med_Genet_2011_May_6_12_63.txt
p.R381Q,"...In the IL23R gene, a rare non-synonymous variant, p.R381Q, appears to be protective against developi...",22,658,BMC_Med_Genet_2011_May_6_12_63.txt
p.R702W,"...f CD, such as 1.9 (95% CI: 1.1-3.2; p = 0.03) for p.R702W, 3.2 (95% CI: 2.2-4.9; p = 6.4*10-9) for p...",41,433,BMC_Med_Genet_2011_May_6_12_63.txt
p.G908R,"... p.R702W, 3.2 (95% CI: 2.2-4.9; p = 6.4*10-9) for p.G908R, and 5.2 (95% CI: 3.3-8.3; p = 2.0*10-12) ...",41,482,BMC_Med_Genet_2011_May_6_12_63.txt
p.G908R,"...ants (D' = 0.99, r2 = 0.17 between rs17221417 and p.G908R and D' = 0.97, r2 = 0.15 between rs2076756...",41,1110,BMC_Med_Genet_2011_May_6_12_63.txt
p.R702W,rs2066844	p.R702W	0.02	0.04	1.85 (1.08-3.18)	0.03,52,36,BMC_Med_Genet_2011_May_6_12_63.txt
p.G908R,rs2066845	p.G908R	0.04	0.11	3.23 (2.15-4.85)	6.39*10-9,53,12,BMC_Med_Genet_2011_May_6_12_63.txt
p.T300A,rs1373692	p.T300A	0.61	0.67	1.29 (1.06-1.58)	0.012,71,36,BMC_Med_Genet_2011_May_6_12_63.txt
p.R381Q,The rare IL23R p.R381Q variant (rs11209026) was more frequently f...,96,16,BMC_Med_Genet_2011_May_6_12_63.txt
p.R702W,"...hich are specific to AJ individuals [28,29], with p.R702W, pG908R, and p.L1007fs accounting for 81% ...",158,726,BMC_Med_Genet_2011_May_6_12_63.txt
p.R702W,"...in our study conferred a slightly higher risk for p.R702W, p.G908R and p.L1007fs (OR of 1.85 (95% CI...",158,1662,BMC_Med_Genet_2011_May_6_12_63.txt
p.G908R,"...udy conferred a slightly higher risk for p.R702W, p.G908R and p.L1007fs (OR of 1.85 (95% CI: 1.08-3....",158,1671,BMC_Med_Genet_2011_May_6_12_63.txt
p.R381Q,"...e IL23R non-synonymous coding variant rs11209026 (p.R381Q) [16], numerous reports including GWAS, ha...",160,134,BMC_Med_Genet_2011_May_6_12_63.txt
p.R381Q,...ciated with the minor allele at IL23R rs11209026 (p.R381Q) was comparable to that reported previousl...,160,366,BMC_Med_Genet_2011_May_6_12_63.txt
p.R2146Q,"...el compound heterozygous mutations, IVS11 + 1 and p.R2146Q, of MYO15A in one (SR903 family) of the 1...",10,67,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"...). Of these, three variants in MYO15A (IVS11 + 1, p.R2146Q, and p.S3474G) were shared by both siblin...",67,187,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S3474G,"...hree variants in MYO15A (IVS11 + 1, p.R2146Q, and p.S3474G) were shared by both siblings. The p.S347...",67,201,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S3474G,"..., and p.S3474G) were shared by both siblings. The p.S3474G variant was ruled out because it was repo...",67,245,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2140Q,"...s and their family. One variant, corresponding to p.R2140Q, was heterozygotic in the patient’s fathe...",67,545,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"...mpound heterozygous mutations, IVS11 + 1G > A and p.R2146Q, are carried by both affected siblings, S...",69,243,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"...the mother (SR-903 M), and the other heterozygous p.R2146Q mutation is from the father (SR-903 F). (...",69,411,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...r (SR-903 F). (B) SR-285 carries the heterozygous p.S2161F mutation in MYO15A, and this mutation was...",69,496,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.Q445R,"...three candidate variants of known deafness genes (p.Q445R in GRHL2, p.T1321S in TECTA, and p.S2161F ...",71,66,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.T1321S,"...riants of known deafness genes (p.Q445R in GRHL2, p.T1321S in TECTA, and p.S2161F in MYO15A); only o...",71,84,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...s genes (p.Q445R in GRHL2, p.T1321S in TECTA, and p.S2161F in MYO15A); only one mutation, p.S2161F i...",71,107,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...ECTA, and p.S2161F in MYO15A); only one mutation, p.S2161F in MYO15A, was shared with an affected si...",71,147,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.G1220R,"...s found to contain another MYO15A coding variant, p.G1220R, which was also shared by both affected s...",71,689,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"...d heterozygous mutations in MYO15A, IVS11 + 1 and p.R2146Q, were found in the SR-903 family, while a...",74,58,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"... the SR-903 family, while a heterozygous variant, p.S2161F was identified in the SR-285 family. All ...",74,131,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"...f the positive charge on the arginine side-chain (p.R2146Q). In the other variant, the polar side ch...",74,768,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,...placed with a non-polar phenylalanine side-chain (p.S2161F). Both alterations are predicted by SIFT ...,74,887,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,SR-903	Chr17:18049349	c.G6437A	p.R2146Q	Exon 29	MyTH4	0/409	Yes	0	0.99	-0.743,82,32,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,SR-285	Chr17:18049394	c.C6482T	p.S2161F	Exon 29	MyTH4	0/409	Yes	0	1	-0.543,84,32,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"Two missense mutations, p.S2161F and p.R2146Q, are located in exon 29, the...",109,25,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"Two missense mutations, p.S2161F and p.R2146Q, are located in exon 29, the first MyTH4 ...",109,38,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2124Q,"...the case of myosin XVA, it has been reported that p.R2124Q and p.P2073S mutations located in the MyT...",109,760,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.P2073S,"...yosin XVA, it has been reported that p.R2124Q and p.P2073S mutations located in the MyTH4 domain int...",109,773,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...present study, we identified two novel mutations, p.S2161F and p.R2146Q, which are located in the My...",109,1036,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"..., we identified two novel mutations, p.S2161F and p.R2146Q, which are located in the MyTH4 domain. T...",109,1049,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,...portant roles in the functions of myosin XVA. The p.R2146Q protein contains a prominent exposed hydr...,109,1219,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.R2146Q,"...FS and CEN [27]. Therefore, we speculate that the p.R2146Q mutation cripples the inter-MyTH4-FERM in...",109,1637,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.G1220R,"...85, we identified two novel nonsynomous variants, p.G1220R and p.S2161F, in the MYO15A gene. Both of...",111,58,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...fied two novel nonsynomous variants, p.G1220R and p.S2161F, in the MYO15A gene. Both of these varian...",111,71,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.G1220R,"...ted sibling. However, as the heterozygous variant p.G1220R was present in the Korean control exome d...",111,200,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...utation in this family. However, another variant, p.S2161F, was absent in 409 ethnically matched con...",111,395,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.G1220R,...for the hearing loss observed in this family: (1) p.G1220R contributes to the phenotype of the SR-28...,111,729,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,...s-yet-unidentified hearing loss gene. Even though p.S2161F was not the causative mutation in this fa...,111,1236,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.S2161F,"...iblings. (B) In family SR-285, only one mutation, p.S2161F in MYO15A, is shared with the affected si...",134,224,BMC_Med_Genet_2013_Jul_17_14_72.txt
p.Pro240Leu,"...e two previously reported pathological mutations, p.Pro240Leu and p.Glu1595Lys, as well as one novel...",10,154,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"... reported pathological mutations, p.Pro240Leu and p.Glu1595Lys, as well as one novel mutation, p.Asn...",10,170,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"... and p.Glu1595Lys, as well as one novel mutation, p.Asn342Ser. The p.Pro240Leu mutation was found in...",10,215,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"..., as well as one novel mutation, p.Asn342Ser. The p.Pro240Leu mutation was found in both families. W...",10,232,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...tional file 3: Table S3). Two missense mutations, p.Pro240Leu and p.Glu1595Lys, were identified to b...",57,252,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...able S3). Two missense mutations, p.Pro240Leu and p.Glu1595Lys, were identified to be compound heter...",57,268,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,...zygous mutations in the proband of SR-106 family. p.Pro240Leu was confirmed in the patient’s father ...,57,369,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...as detected. SR-209 family carried two mutations, p.Pro240Leu and p.Asn342Ser in the CDH23. Both var...",57,625,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...209 family carried two mutations, p.Pro240Leu and p.Asn342Ser in the CDH23. Both variants were also ...",57,641,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,...riants were also found in an affected sibling and p.Pro240Leu was confirmed in the father by Sanger ...,57,724,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...wo patients and one patient were heterozygous for p.Pro240Leu (2.15%) and p.Glu1595Lys (1.07%), resp...",57,977,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...ent were heterozygous for p.Pro240Leu (2.15%) and p.Glu1595Lys (1.07%), respectively. Direct sequenc...",57,1001,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,...tched negative controls (over 700). The mutations p.Asn342Ser and p.Glu1595Lys were absent in all co...,57,1138,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...ontrols (over 700). The mutations p.Asn342Ser and p.Glu1595Lys were absent in all controls, and p.Pr...",57,1154,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...and p.Glu1595Lys were absent in all controls, and p.Pro240Leu was detected in 2 (0.24%) of 818 Korea...",57,1200,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...n family SR-106, compound heterozygous mutations, p.Pro240Leu and p.Glu1595Lys, were identified. One...",59,216,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"... compound heterozygous mutations, p.Pro240Leu and p.Glu1595Lys, were identified. One heterozygous p....",59,232,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...d p.Glu1595Lys, were identified. One heterozygous p.Pro240Leu mutation was confirmed in the father. ...",59,280,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...n family SR-209, compound heterozygous mutations, p.Pro240Leu and p.Asn342Ser, were carried by an af...",59,385,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"... compound heterozygous mutations, p.Pro240Leu and p.Asn342Ser, were carried by an affected sibling a...",59,401,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,...carried by an affected sibling and a heterozygous p.Pro240Leu mutation by the father. All pathogenic...,59,469,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"c.C719T	p.Pro240Leu	8	EC3	ㅡ	DAMAGING/0.02	0.999	−1	SR-106,...",75,9,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,c.A1025G	p.Asn342Ser	11	EC3	DXNDN	DAMAGING/0	0.905	−1	SR-20...,76,10,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,c.G4783A	p.Glu1595Lys	36	EC15	DRE	DAMAGING/0	0.987	−1	SR-10...,77,10,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...g two previously reported pathological mutations, p.Pro240Leu and p.Glu1595Lys, and one novel mutati...",85,97,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"... reported pathological mutations, p.Pro240Leu and p.Glu1595Lys, and one novel mutation, p.Asn342Ser ...",85,113,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...o240Leu and p.Glu1595Lys, and one novel mutation, p.Asn342Ser (Table 2). The ConSeq server revealed ...",85,151,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,...ium binding below the threshold of detection. The p.Glu1595Lys mutation reduces the numbers of oxyge...,85,761,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...e polar and uncharged amino acids themselves, the p.Asn342Ser mutation involves the change from a sm...",85,994,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,...alcium affinity and impairs protein function like p.Glu1595Lys. The p.Pro240Leu mutation does not di...,85,1325,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,...d impairs protein function like p.Glu1595Lys. The p.Pro240Leu mutation does not directly interfere w...,85,1343,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...is longer and more flexible (Figure 2). Thus, the p.Pro240Leu substitution may affect protein stabil...",85,1631,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,...re wild-type and those of B and D are mutant. The p.Asn342Ser in EC3 and p.Glu1595Lys in EC15 are as...,87,459,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,...of B and D are mutant. The p.Asn342Ser in EC3 and p.Glu1595Lys in EC15 are associated with highly co...,87,482,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Ala361Ser,2	Chr10:73377097	11	c.G1081T	p.Ala361Ser	.	.	1/30	Novel,100,30,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Val424Met,3	Chr10:73405717	12	c.G1270A	p.Val424Met	rs2305207	.	1/30	rs2305207,101,30,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asp428Asn,4	Chr10:73405729	12	c.G1282A	p.Asp428Asn	rs188376296	1 (SR-68)	2/128	rs18837629...,102,30,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Gly490Ala,5	Chr10:73434888	14	c.G1469C	p.Gly490Ala	rs1227049	8	14/30	[5],103,30,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Ser496Asn,6	Chr10:73434906	14	c.G1487A	p.Ser496Asn	rs10999947	7	54/128	[5],104,30,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg1010His,8	Chr10:73466729	25	c.G3029A	p.Arg1010His	.	.	1/30	Novel,106,30,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Val1335Ala,10	Chr10:73492032	31	c.T4004C	p.Val1335Ala	.	.	1/30	Novel,108,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn1351Asp,11	Chr10:73492079	31	c.A4051G	p.Asn1351Asp	rs1227065	16	29/30	[5],109,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg1437Gln,12	Chr10:73498355	33	c.G4310A	p.Arg1437Gln	rs56181447	5	8/30	[5],110,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg1588Trp,13	Chr10:73501595	36	c.C4762T	p.Arg1588Trp	.	.	1/30	[5],111,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Ala1575Thr,14	Chr10:73501556	36	c.G4723A	p.Ala1575Thr	rs1227051	16	28/30	[5],112,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Val1675Ile,15	Chr10:73537614	37	c.G5023A	p.Val1675Ile	rs17712523	8	7/30	[5],113,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg1804Gln,16	Chr10:73544086	40	c.G5411A	p.Arg1804Gln	rs3802711	10	16/30	[5],114,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asp1806Glu,17	Chr10:73544093	40	c.C5418G	p.Asp1806Glu	rs74145660	3	6/30	[5],115,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Thr1999Ser,18	Chr10:73550117	44	c.C5996G	p.Thr1999Ser	rs11592462	6	8/30	[5],116,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu2044Lys,19	Chr10:73550969	45	c.G6130A	p.Glu2044Lys	rs10466026	12	26/30	[5],117,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg2358Gln,21	Chr10:73558886	49	c.G7073A	p.Arg2358Gln	rs4747194	12	26/30	[5],119,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro2380Leu,22	Chr10:73558952	49	c.C7139T	p.Pro2380Leu	rs4747195	12	26/30	[5],120,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Met2531Val,23	Chr10:73562763	52	c.A7591G	p.Met2531Val	.	.	1/30	Novel,121,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Ala3080Thr,25	Chr10:73571307	62	c.G9238A	p.Ala3080Thr	.	1 (SR-1016)	3/128	Novel,123,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Phe3125Leu,26	Chr10:73571765	64	c.T9373C	p.Phe3125Leu	rs45583140	2	15/30	rs45583140,124,31,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"We identified three CDH23 mutations, p.Pro240Leu, p.Glu1595Lys, and p.Asn342Ser, in 2 (...",132,38,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"We identified three CDH23 mutations, p.Pro240Leu, p.Glu1595Lys, and p.Asn342Ser, in 2 (15%) of 13 Ko...",132,51,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...e CDH23 mutations, p.Pro240Leu, p.Glu1595Lys, and p.Asn342Ser, in 2 (15%) of 13 Korean families with...",132,69,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...creened for eight mutations, including the three (p.Pro240Leu, p.Asn342Ser and p.Glu1595Lys) detecte...",132,342,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...ight mutations, including the three (p.Pro240Leu, p.Asn342Ser and p.Glu1595Lys) detected in the pres...",132,355,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...including the three (p.Pro240Leu, p.Asn342Ser and p.Glu1595Lys) detected in the present study, and f...",132,371,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg301Gln,"...) detected in the present study, and five others (p.Arg301Gln, p.Glu956Lys, p.Arg1417Trp, p.Gln1716P...",132,433,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu956Lys,"... the present study, and five others (p.Arg301Gln, p.Glu956Lys, p.Arg1417Trp, p.Gln1716Pro, and p.Arg...",132,446,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg1417Trp,"...study, and five others (p.Arg301Gln, p.Glu956Lys, p.Arg1417Trp, p.Gln1716Pro, and p.Arg2029Trp) that...",132,459,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Gln1716Pro,"...e others (p.Arg301Gln, p.Glu956Lys, p.Arg1417Trp, p.Gln1716Pro, and p.Arg2029Trp) that occur at rela...",132,473,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Arg2029Trp,"...Gln, p.Glu956Lys, p.Arg1417Trp, p.Gln1716Pro, and p.Arg2029Trp) that occur at relatively high freque...",132,491,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"... one patient, respectively, were heterozygous for p.Pro240Leu and p.Glu1595Lys, and no other mutatio...",132,718,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...spectively, were heterozygous for p.Pro240Leu and p.Glu1595Lys, and no other mutation was detected. ...",132,734,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...p.Glu1595Lys, and no other mutation was detected. p.Pro240Leu was reported in Japanese families with...",132,784,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,...ant causes of non-syndromic hearing loss and that p.Pro240Leu accounted for nearly 43.3% (45/105) of...,132,1015,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...with ARNSHL caused by CDH23 mutations carried the p.Pro240Leu mutation and, additionally, two of 93 ...",132,1189,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Pro240Leu,"...atients were heterozygous for the mutation. Thus, p.Pro240Leu is the most common cause of CDH23-asso...",132,1303,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,... of CDH23-associated ARNSHL in Asian populations. p.Glu1595Lys was present in 1 of 93 patients. Astu...,132,1389,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...nd in the EC domain. Of the three mutations, two (p.Glu1595Lys and p.Asn342Ser) affected highly cons...",134,677,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...in. Of the three mutations, two (p.Glu1595Lys and p.Asn342Ser) affected highly conserved EC calcium-...",134,694,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,"...ification, and dimerization of CDH23 [15,16]. The p.Glu1595Lys mutation may disrupt a conserved LDRE...",134,913,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Glu1595Lys,...dent interactions [16]. Molecular modeling of the p.Glu1595Lys mutation shows impairment of calcium ...,134,1147,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asn342Ser,"...ith either CDH23 or other proteins. Likewise, the p.Asn342Ser mutation is also located in a highly c...",134,1459,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Asp428Asn,...uld not conclude that it is a causative mutation. p.Asp428Asn in SR-68 was also heterozygous. DNA sa...,136,405,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Val2283Ile,...onfirm its pathogenicity by segregation analysis. p.Val2283Ile and p.Phe2801Val were identified as c...,136,571,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.Phe2801Val,...enicity by segregation analysis. p.Val2283Ile and p.Phe2801Val were identified as compound heterozyg...,136,588,BMC_Med_Genet_2014_Apr_28_15_46.txt
p.R5205H,... a variant of DDHD1 on 14q. The variant of HMCN1 (p.R5205H) showed the best co-segregation in the fa...,10,398,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.A4704V,"...sequencing. Additionally, rare missense variants (p.A4704V, p.T5004I, and p.H5244Q) were detected in...",10,532,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.T5004I,".... Additionally, rare missense variants (p.A4704V, p.T5004I, and p.H5244Q) were detected in three unr...",10,542,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.H5244Q,"..., rare missense variants (p.A4704V, p.T5004I, and p.H5244Q) were detected in three unrelated Kosovo ...",10,556,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.V121I,"...r was a rare variant. The novel variant (c.G361A, p.V121I) is located in the Contactin 2 gene (CNTN2...",144,121,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.R5205H,"...e non-synonymous variant (rs150188026, c.G15614A, p.R5205H, MAF 0.018) is located in the Hemicentin ...",144,293,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.A4704V,"... very rare missense variants in HMCN1 (c.C14111T, p.A4704V, MAF 0.001; c.C15011T, p.T5004I, MAF 0.00...",144,587,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.T5004I,"...HMCN1 (c.C14111T, p.A4704V, MAF 0.001; c.C15011T, p.T5004I, MAF 0.008, and c.C15732G, p.H5244Q, MAF ...",144,619,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.H5244Q,"...1; c.C15011T, p.T5004I, MAF 0.008, and c.C15732G, p.H5244Q, MAF 0.005) (Table 2 and Table 3). The ot...",144,655,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.V393A,"... DDHD domain containing 1 gene (DDHD1) (c.T1178C, p.V393A) and it causes an amino acid substitution ...",144,818,BMC_Med_Genet_2014_Oct_23_15_115.txt
p.R928C,"c.2782C > T	p.R928C	Bethlem myopathy, #158810",107,14,BMC_Med_Genet_2015_Jul_16_16_49.txt
p.E1586D,"c.4758A > C	p.E1586D	Alagille syndrome 2, #610205",111,14,BMC_Med_Genet_2015_Jul_16_16_49.txt
p.R928C,"...utation in a collagen gene (COL6A3) (c.2782C > T, p.R928C) was identified. Collagen genes encode str...",116,69,BMC_Med_Genet_2015_Jul_16_16_49.txt
p.E1586D,"... [17]. Likewise, the NOTCH2 mutation(c.4758A > C, p.E1586D) identified in the index patient and his ...",118,440,BMC_Med_Genet_2015_Jul_16_16_49.txt
p.Gly243Arg,"...ants that were filtered to a homozygous mutation (p.Gly243Arg) in the FBXO32 gene, located within th...",11,196,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.His356Tyr,"...bases, resulting in only two homozygous variants; p.His356Tyr in OC90 and p.Gly243Arg in FBXO32. The...",64,579,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,... two homozygous variants; p.His356Tyr in OC90 and p.Gly243Arg in FBXO32. The OC90 variant was exclud...,64,603,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,"...glycine with arginine at amino acid position 243 (p.Gly243Arg, Fig. 5a). This missense mutation segr...",64,1368,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.G243R,"a The homozygous mutation (c.727G > C, p.G243R) is indicated by the arrow in the upper pa...",65,40,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,...rediction analysis for functional consequences of p.Gly243Ar,71,73,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,...tilized to predict the functional consequences of p.Gly243Arg (c.727G > C). The Polyphen2 program pr...,72,150,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,...a score of −3.624. SNPs&GO analysis predicted the p.Gly243Arg change as “disease” with a reliability...,72,398,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,... an essential function (Fig. 5b). We also modeled p.Gly243Arg of FBXO32 on a template structure adap...,72,834,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Gly243Arg,...ral factors pertinent to the identified mutation (p.Gly243Arg) support the suggestion that FBXO32 is...,91,100,BMC_Med_Genet_2016_Jan_14_17_3.txt
p.Phe174Ser,...London 28710.1186/s12881-016-0287-1Case ReportThe p.Phe174Ser mutation is associated with mild forms...,3,122,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,"...gous for a known pathogenic mutation (c.724C > T, p.Arg242Cys) and a mutation that has only been rep...",8,248,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"...ported once in a Portuguese patient (c.521 T > C, p.Phe174Ser) whose pathogenicity has not been yet ...",8,347,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,...sessed. We compared the two patients carrying the p.Phe174Ser variant and concluded that this varian...,8,449,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"... this report, we confirm the pathogenicity of the p.Phe174Ser variant and we also provide evidence o...",11,317,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,"...gous for a known pathogenic mutation (c.724C > T, p.Arg242Cys) and a mutation that has only been rep...",23,142,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"...d once in the Portuguese population (c.521 T > C, p.Phe174Ser) [11]",23,246,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"...ealed the presence of two mutations: c.521 T > C (p.Phe174Ser), inherited from the mother and c.724C...",36,438,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,"...74Ser), inherited from the mother and c.724C > T (p.Arg242Cys), inherited from the father, confirmin...",36,494,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,Our case had two mutations in the DHCR7 gene: p.Arg242Cys and p.Phe174Ser. Whilst the p.Arg242Cy...,40,47,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,... two mutations in the DHCR7 gene: p.Arg242Cys and p.Phe174Ser. Whilst the p.Arg242Cys mutation has b...,40,63,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,...CR7 gene: p.Arg242Cys and p.Phe174Ser. Whilst the p.Arg242Cys mutation has been repeatedly reported ...,40,87,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"...ported in patients affected by SLOS [14, 15], the p.Phe174Ser has only been reported in one Portugue...",40,180,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"a Chromatograms showing the c.521 T > C (p.Phe174Ser), and the c.724C > T (p.Arg242Cys) mut...",43,42,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,"...he c.521 T > C (p.Phe174Ser), and the c.724C > T (p.Arg242Cys) mutations. b In silico programs showi...",43,76,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"...lico programs showing the predicted effect of the p.Phe174Ser mutation on the DHCR7. SNP&GO, http://...",43,157,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,... mutations or with two mutations in loop 8–9. The p.Phe174Ser and the p.Arg242Cys mutations are in t...,48,530,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Arg242Cys,...wo mutations in loop 8–9. The p.Phe174Ser and the p.Arg242Cys mutations are in the TM3 and TM5 domai...,48,550,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,...eviously reported Portuguese patient carrying the p.Phe174Ser mutation are both affected by a form o...,48,976,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,...differences between our case and the one with the p.Phe174Ser mutation that was previously reported....,48,1139,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,"...e observations, it is possible to assume that the p.Phe174Ser variant is associated with mild forms ...",48,1260,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,...able 1 Clinical features of patients carrying the p.Phe174Ser varian,48,1369,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Phe174Ser,...study offers further clinical significance to the p.Phe174Ser variant and provides evidence for its ...,71,369,BMC_Med_Genet_2016_Mar_11_17_22.txt
p.Gly1349Asp,"...e, including mutation description syntaxes (e.g. 'p.Gly1349Asp'), reported gene name (e.g. 'CFTR'), ...",46,180,BMC_Med_Genomics_2013_Jan_23_6(Suppl_1)_S16.txt
p.S110S,rs1780316	c.330 T > C	p.S110S	1.00	0.94	0.95,79,23,BMC_Musculoskelet_Disord_2016_Aug_9_17_332.txt
p.Y263H,rs3200254	c.787 T > C	p.Y263H	0.20	0.17	0.11,80,23,BMC_Musculoskelet_Disord_2016_Aug_9_17_332.txt
p.P292P,rs3200255	c.876A > G	p.P292P	0.20	0.17	0.11,81,22,BMC_Musculoskelet_Disord_2016_Aug_9_17_332.txt
p.V522A,rs34605986	c.1565 T > C	p.V522A	0.10	0.00	0.10,82,25,BMC_Musculoskelet_Disord_2016_Aug_9_17_332.txt
p.Arg247Pro,... two SMARCAL1 mutations: a novel missense change (p.Arg247Pro) and a well-known nonsense mutation (p...,7,450,BMC_Nephrol_2014_Mar_3_15_41.txt
p.Arg247Pro,"...resulting in an arginine-to-proline substitution (p.Arg247Pro), inherited by the mother; and a nonse...",28,198,BMC_Nephrol_2014_Mar_3_15_41.txt
p.Arg247Pro,...pound heterozygous for a novel missense mutation (p.Arg247Pro) and a well-known nonsense mutation (p...,35,202,BMC_Nephrol_2014_Mar_3_15_41.txt
p.Arg247Pro,"...9], displayed a mild form. The missense mutation (p.Arg247Pro) within the first HARP domain (HARP1),...",35,313,BMC_Nephrol_2014_Mar_3_15_41.txt
p.G2019S,... the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequenci...,6,204,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,"...ntly sporadic PD. The LRRK2 mutation c.6055G > A; p.G2019S, accounts for 1–2% of typical sporadic PD...",20,617,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,We had previously shown that the c.6055G > A; p.G2019S mutation in LRRK2 is common in Portuguese...,22,47,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,...iously been found to carry the LRRK2 c.6055G > A; p.G2019S mutation (n = 11). This selection led to ...,25,1159,BMC_Neurol_2008_Jan_22_8_1.txt
p.E395X,...ed data consistent with a homozygous c.1183G > T; p.E395X mutation and a duplication of exon 9; beca...,45,607,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,"...amples tested positive for the LRRK2 c.6055G > A; p.G2019S mutation, sample S12 and sample S7. Notab...",67,56,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,...vious report [15] we showed that the c.6055G > A; p.G2019S LRRK2 mutation underlies about 6% of late...,76,61,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,...opulation. While we did not find any c.6055G > A; p.G2019S carriers in the 20 late-onset patients st...,76,190,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,"...tients studied here, we did identify c.6055G > A; p.G2019S in 2 of 46 early-onset cases. One of thes...",76,281,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,...amples previously found to carry the c.6055G > A; p.G2019S mutation we calculate that this mutation ...,76,688,BMC_Neurol_2008_Jan_22_8_1.txt
p.G2019S,"...r of mutations: the frequency of the c.6055G > A; p.G2019S is one of the highest in Europe, and in t...",85,208,BMC_Neurol_2008_Jan_22_8_1.txt
p.E64D,...llnik B Tong L Kruger R Riess O  Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson di...,114,189,BMC_Neurol_2008_Jan_22_8_1.txt
p.Q648X,... the identification of a novel nonsense mutation (p.Q648X) and three previously known mutations,10,233,BMC_Neurol_2011_Oct_1_11_119.txt
p.Q648X,...(c.1942 C>T) resulting in a premature stop codon (p.Q648X). In family MCP26 an already reported homo...,37,326,BMC_Neurol_2011_Oct_1_11_119.txt
p.Arg438His,... mutations were identified in exon 10 (c.1313G>A; p.Arg438His) and 11 (c.1531G>A; p.Asp511Asn) in fa...,37,647,BMC_Neurol_2011_Oct_1_11_119.txt
p.Asp511Asn,"...on 10 (c.1313G>A; p.Arg438His) and 11 (c.1531G>A; p.Asp511Asn) in families MCP35 and MCP3, respectiv...",37,679,BMC_Neurol_2011_Oct_1_11_119.txt
p.Q648X,"...n family MCP67, harboring the truncating mutation p.Q648X, the affected subjects also have severe cl...",84,476,BMC_Neurol_2011_Oct_1_11_119.txt
p.Q78X,...tion in exon 3 of CTNNB1 (NM_001098209): c.C232T; p.Q78X (Fig. 1B).Fig. 1 Filtering strategy used fo...,128,1591,BMC_Neurol_2016_Mar_12_16_35.txt
p.Q78X,...panel (a). DNA electrophoregram with the c.C232T; p.Q78X mutation in exon 3 of CTNNB1 (b,128,1765,BMC_Neurol_2016_Mar_12_16_35.txt
p.Q78X,...atient has a de novo mutation in CTNNB1 (c.C232T; p.Q78X) which is localized in the N-terminal domai...,141,357,BMC_Neurol_2016_Mar_12_16_35.txt
p.R416W,"...same heterozygous missense mutation, c.1246C > T, p.R416W, despite of no neurological symptoms in he...",8,834,BMC_Neurol_2016_Nov_4_16_211.txt
p.R416W,...rginine to tryptophan at amino acid position 416 (p.R416W). Her daughter’s genomic DNA showed the sa...,48,294,BMC_Neurol_2016_Nov_4_16_211.txt
p.R416W,"...ine, Aarrowhead), leading to amino acid change in p.R416W (arginine > tryptophan",48,769,BMC_Neurol_2016_Nov_4_16_211.txt
p.R416W,"... missense mutation in the GFAP gene, c.1246C > T, p.R416W was identified, which was already shown to...",53,189,BMC_Neurol_2016_Nov_4_16_211.txt
p.D78N,...	Male	62	Mild cervicomedullary atrophy	c.232G > A	p.D78N,79,65,BMC_Neurol_2016_Nov_4_16_211.txt
p.V87G,"...and spinal cord, Periventricular rim	c. 274 T > G	p.V87G",80,102,BMC_Neurol_2016_Nov_4_16_211.txt
p.V87G,"...e matter lesion, periventricular rim	c. 274 T > G	p.V87G",81,124,BMC_Neurol_2016_Nov_4_16_211.txt
p.R88C,a<4	Frontal white matter abnormality	c.276C > T	p.R88C,83,49,BMC_Neurol_2016_Nov_4_16_211.txt
p.E205K,...of medulla oblongata and cervical cord	c.613G > A	p.E205K,84,126,BMC_Neurol_2016_Nov_4_16_211.txt
p.R330G,"...eriventricular rim, atrophy of medulla	c.988C > G	p.R330G",85,75,BMC_Neurol_2016_Nov_4_16_211.txt
p.E332K,c.994G > A	p.E332K,86,12,BMC_Neurol_2016_Nov_4_16_211.txt
p.L331P,...ep frontal white matter and caudates	c.1006 T > C	p.L331P,87,111,BMC_Neurol_2016_Nov_4_16_211.txt
p.N386S,... cord medullaoblongata and cerebellar	c.1157A > G	p.N386S,88,103,BMC_Neurol_2016_Nov_4_16_211.txt
p.S398Y,... medulla oblongata and cervical cord	c. 1193C > A	p.S398Y,89,128,BMC_Neurol_2016_Nov_4_16_211.txt
p.R416W,"...the cerebellum, medulla, pons changes	c.1260C > T	p.R416W",91,72,BMC_Neurol_2016_Nov_4_16_211.txt
p.P47L,c.154C > T	p.P47L,92,12,BMC_Neurol_2016_Nov_4_16_211.txt
p.R416W,"... missense mutation of the GFAP gene, c.1246C > T, p.R416W, has been reported to be one of the causes...",99,408,BMC_Neurol_2016_Nov_4_16_211.txt
p.Glu809X,...2425G > T) responsible of a premature stop codon (p.Glu809X),80,728,BMC_Psychiatry_2015_May_7_15_107.txt
p.Gly12Asp,**WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser,84,23,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly12Val,**WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser,84,41,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly12Ser,...ldtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser,84,59,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly13Asp,G13D: p.Gly13Asp,86,7,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly12Asp,...ld-type result for sample 14 which was actually a p.Gly12Asp (G12D) mutation. While this sample was ...,90,79,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly12Asp,"...G > A change was visible by sequencing indicating p.Gly12Asp mutation, but was not reported because ...",90,406,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly12Asp,"...ild-type; two labs reported a mutation in exon 12 p.Gly12Asp, and three labs were consistent with th...",92,125,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Gly12Asp,"... re-testing. Laboratory #2 found the same result (p.Gly12Asp) in the second set of slides, but there...",92,478,BMC_Res_Notes_2012_Apr_25_5_196.txt
p.Leu1077Pro,...500-6-461Short ReportPhenotypic expression of the p.Leu1077Pro CFTR mutation in Sicilian cystic fibr...,3,156,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,The p.Leu1077Pro CFTR mutation was firstly described i...,4,5,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...tion collected in database CFTR2 lead to consider p.Leu1077Pro as a severe CF mutation. Although it ...,4,192,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"...tation. Although it is typical of Southern Italy, p.Leu1077Pro is not included in the mutation panel...",4,272,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...atients. 4 patients who were heterozygous for the p.Leu1077Pro mutation were included in the study,7,106,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"In our Cystic Fibrosis Centre, the prevalence of p.Leu1077Pro is 3.6% among all mutations. All pati...",9,50,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,We found that the p.Leu1077Pro CFTR mutation is associated with a cl...,12,19,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...CFTR2 database. The relatively high prevalence of p.Leu1077Pro associated with the severe clinical c...,12,169,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,The p.Leu1077Pro (L1077P) mutation consists in a trans...,21,5,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,... Bozon et al. [8] firstly found evidence that the p.Leu1077Pro was associated with a pancreatic suff...,23,192,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"... 40 patients with this mutation, lead to consider p.Leu1077Pro as a severe CF mutation, associated w...",25,119,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"...it should be predictive of a severe CF phenotype, p.Leu1077Pro is not included in the mutation panel...",27,154,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...linical features in Sicilian patients bearing the p.Leu1077Pro CFTR mutation followed in our Cystic ...,29,114,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...range 7 – 20 years) who were heterozygous for the p.Leu1077Pro mutation were included in the study: ...,33,431,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Asn1303Lys,...tation in the second allele while one carried the p.Asn1303Lys (N1303K) mutation. The group included...,33,585,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,1	M	7 yrs	14.57 (Underweight)	Birth	p.Phe508del/p.Leu1077Pro	112	84/43,40,49,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,2	M	10	19.80 (Normal weight)	Birth	p.Phe508del/p.Leu1077Pro	101	155/215,41,48,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,3	M	12	19.63 (Normal weight)	Birth	p.Phe508del/p.Leu1077Pro	97	181/100,42,48,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Asn1303Lys,4	F	20	16.44 (Underweight)	4 months	p.Asn1303Lys/p.Leu1077Pro	108	NA,43,37,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,4	F	20	16.44 (Underweight)	4 months	p.Asn1303Lys/p.Leu1077Pro	108	NA,43,50,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...ing is routinely performed in our laboratory. The p.Leu1077Pro mutation was identified by denaturing...,62,541,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"...icilian Cystic Fibrosis Centre, the prevalence of p.Leu1077Pro is 3.6% among all mutations",65,67,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,The present study provides evidence that the p.Leu1077Pro is a relatively frequent mutation ass...,87,46,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,The p.Leu1077Pro mutation consists in a transition T t...,89,5,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"Nevertheless p.Leu1077Pro mutation, although belonging to the c...",93,14,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,"On this regard, the mutation p.Leu1077Pro is typical of Southern Italy, overall...",97,30,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...irth by sweat test. All of them had a p.Phe508del/p.Leu1077Pro genotype,103,230,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Asn1303Lys,...sweat test which resulted pathological. She had a p.Asn1303Lys/p.Leu1077Pro genotype,105,282,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,...ich resulted pathological. She had a p.Asn1303Lys/p.Leu1077Pro genotype,105,295,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Asn1303Lys,"...on with a severe mutation such as p.Phe508del and p.Asn1303Lys, it is clear that only a follow-up co...",116,299,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.Leu1077Pro,The relatively high prevalence of p.Leu1077Pro associated with the severe clinical c...,118,35,BMC_Res_Notes_2013_Nov_13_6_461.txt
p.I852T,"...three siblings share the same variant c.2555T >C (p.I852T) in the homozygous state. Accordingly, dia...",57,306,BMC_Res_Notes_2016_Feb_13_9_91.txt
p.I852T,...led a homozygote state of the variant c.2555T >C (p.I852T),70,405,BMC_Res_Notes_2016_Feb_13_9_91.txt
p.I852T,"...nd CRB1 mutations in 7.4 % of them, with the same p.I852T mutation (of our patients) in two patients...",72,188,BMC_Res_Notes_2016_Feb_13_9_91.txt
p.I852T,"...o have CRB1 mutations, especially the c.2555T >C (p.I852T) homozygote variant searching for any vasc...",83,235,BMC_Res_Notes_2016_Feb_13_9_91.txt
p.Arg528Cys,"...nced, and a novel missense mutation, c.1582C > T (p.Arg528Cys), in CACNA1S was detected. Detection o...",7,977,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg528Cys,"...dentified a novel dominant mutation, c.1582C > T (p.Arg528Cys), in CACNA1S that causes hypokalaemic ...",10,55,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg528Cys,"...novel missense mutation, c.1582C > T, in CACNA1S (p.Arg528Cys) (Figure 1). In his family, the mutati...",35,394,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg528Cys,"...aled a missense mutation in CACNA1S, resulting in p.Arg528Cys. This mutation had not been reported p...",42,644,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg528His,"...ons involve the 528th codon of CACNA1S, including p.Arg528His and p.Arg528Gly [5, 13]. The arginine ...",42,1032,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg528Gly,"...528th codon of CACNA1S, including p.Arg528His and p.Arg528Gly [5, 13]. The arginine residue encoded ...",42,1048,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg528Cys,"...ralysis, we identified a novel dominant mutation, p.Arg528Cys, of CACNA1S causing HOPPK, which is th...",47,157,BMC_Urol_2014_Nov_28_14_96.txt
p.Arg650Cys,"...sting was performed and that showed a c.1948 C>T (p.Arg650Cys) mutation in fibrillin-1 gene, confirm...",47,87,Cureus_8(5)_e619.txt
p.R206H,"...1 causes an arginine-to-histidine substitution at p.R206H in ALK2 within the GS domain in FOP, makin...",29,1735,Bone_Res_2015_Apr_14_3_15005.txt
p.L196P,"...e positions of the mutation in the GS domain are: p.L196P, p.P198-F199delinsL, p.R202I, and p.Q207E....",29,2642,Bone_Res_2015_Apr_14_3_15005.txt
p.R202I,"...n the GS domain are: p.L196P, p.P198-F199delinsL, p.R202I, and p.Q207E.70–72 Moreover, several mutat...",29,2671,Bone_Res_2015_Apr_14_3_15005.txt
p.Q207E,"...in are: p.L196P, p.P198-F199delinsL, p.R202I, and p.Q207E.70–72 Moreover, several mutations noticed ...",29,2684,Bone_Res_2015_Apr_14_3_15005.txt
p.R258S,"...ed in the serine/threonine kinase domain, such as p.R258S, p.G325A, p.G328E/R/W, p.G356D, and p.R375...",29,2781,Bone_Res_2015_Apr_14_3_15005.txt
p.G325A,"... serine/threonine kinase domain, such as p.R258S, p.G325A, p.G328E/R/W, p.G356D, and p.R375P.73–75Fi...",29,2790,Bone_Res_2015_Apr_14_3_15005.txt
p.G328E,"...hreonine kinase domain, such as p.R258S, p.G325A, p.G328E/R/W, p.G356D, and p.R375P.73–75Figure 2 sh...",29,2799,Bone_Res_2015_Apr_14_3_15005.txt
p.G356D,"...se domain, such as p.R258S, p.G325A, p.G328E/R/W, p.G356D, and p.R375P.73–75Figure 2 shows that the ...",29,2812,Bone_Res_2015_Apr_14_3_15005.txt
p.R375P,"...ch as p.R258S, p.G325A, p.G328E/R/W, p.G356D, and p.R375P.73–75Figure 2 shows that the FOP mutations...",29,2825,Bone_Res_2015_Apr_14_3_15005.txt
p.Thr52Pro,"...giectasia type 2 with a novel mutation, c.154A>C (p.Thr52Pro), in the ALK1/ACVRL1 gene Neurol Clin N...",240,149,Bone_Res_2015_Apr_14_3_15005.txt
p.V600E,"...ino acid 600 in the kinase domain of the protein (p.V600E, previously known as p.V599E; Smalley and ...",17,441,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V599E,"...main of the protein (p.V600E, previously known as p.V599E; Smalley and Herlyn, 2004). The resulting ...",17,470,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600E,"...id 600 within the BRAF gene. The assay can detect p.V600E, p.V600K and p.V600D mutations within the ...",43,385,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600K,"...thin the BRAF gene. The assay can detect p.V600E, p.V600K and p.V600D mutations within the BRAF gene...",43,394,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600D,"...F gene. The assay can detect p.V600E, p.V600K and p.V600D mutations within the BRAF gene, but does n...",43,406,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600E,"... HT29 cell line, known to be heterozygous for the p.V600E mutation. Human genomic DNA (Roche, Basel,...",49,120,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600E,"... cell line HT29 (known to be heterozygous for the p.V600E mutation), several serial dilution studies...",71,60,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600K,"...plex g.1798-1799GT>AA changes resulting in a BRAF p.V600K alteration, rather than the more common p....",74,521,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600E,"...F p.V600K alteration, rather than the more common p.V600E (g.1799T>A). Sequencing detected two sampl...",74,569,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.N581S,...ecific ARMS assays in this study: BRAF g.1742A>T (p.N581S) and g.1801A>G (p.K601E). Eighteen mutatio...,74,742,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.K601E,...is study: BRAF g.1742A>T (p.N581S) and g.1801A>G (p.K601E). Eighteen mutations were detected by ARMS...,74,766,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600E,...S. Sequencing had confirmed these mutations to be p.V600E in 42 cases and p.V600K in 3 cases. A furt...,76,158,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.V600K,...med these mutations to be p.V600E in 42 cases and p.V600K in 3 cases. A further tumour sample was sh...,76,182,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.K601E,"...s. A further tumour sample was shown to harbour a p.K601E mutation, which was not detectable by the ...",76,249,Br_J_Cancer_2009_Nov_17_101(10)_1724-1730.txt
p.Gly12Val,"...used as reference for mutations in KRAS codon 12 (p.Gly12Val, heterozygous) and 13 (p.Gly13Asp, hete...",42,204,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,"... KRAS codon 12 (p.Gly12Val, heterozygous) and 13 (p.Gly13Asp, heterozygous), respectively. DNA obtai...",42,238,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,...ion melting analysis was able to discriminate the p.Gly12Val (H441) and the p.Gly13Asp (HCT116) DNA ...,54,63,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,...ble to discriminate the p.Gly12Val (H441) and the p.Gly13Asp (HCT116) DNA from KRAS-WT DNA (PC-9). F...,54,89,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,...3%. We were able to detect as little as 3% of MUT p.Gly12Val DNA in a WT background,54,429,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,...all four samples showing aberrant melting curves (p.Gly12Val n=2; p.Gly12Asp n=1 and p.Gly13Asp n=1)...,56,808,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Asp,... showing aberrant melting curves (p.Gly12Val n=2; p.Gly12Asp n=1 and p.Gly13Asp n=1),56,824,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,...elting curves (p.Gly12Val n=2; p.Gly12Asp n=1 and p.Gly13Asp n=1),56,843,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,...tated patient who achieved a stable disease had a p.Gly13Asp mutation. The disease control rate (obj...,61,505,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,"...The horizontal line indicates WT control, and the p.Gly13Asp p.Gly12Val labelled lines indicate in d...",83,126,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,"...tal line indicates WT control, and the p.Gly13Asp p.Gly12Val labelled lines indicate in duplicate th...",83,137,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,"...ions of DNA from H441 cells that harbour the KRAS p.Gly12Val mutation, mixed with the KRAS WT PC-9 c...",85,135,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,"...pond to HRMA mutated samples (from top to bottom: p.Gly13Asp, p.Gly12Val and the p.Gly12Asp). Corres...",87,290,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,"... mutated samples (from top to bottom: p.Gly13Asp, p.Gly12Val and the p.Gly12Asp). Corresponding WT s...",87,302,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Asp,"...rom top to bottom: p.Gly13Asp, p.Gly12Val and the p.Gly12Asp). Corresponding WT sequencing electroph...",87,321,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly13Asp,"...p to bottom, the first electropherogram shows the p.Gly13Asp HRMA-mutated sample, the second the p.G...",87,476,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Asp,"...he p.Gly13Asp HRMA-mutated sample, the second the p.Gly12Asp HRMA-mutated samples and the third and ...",87,523,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly12Val,...mutated samples and the third and fourth show two p.Gly12Val HRMA-mutated samples,87,589,Br_J_Cancer_2012_Aug_7_107(4)_626-631.txt
p.Gly2891Asp,...se activity. One missense ATM mutation c.8672G>A (p.Gly2891Asp) and a c.1A>G substitution were ident...,10,374,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...ion were identified. In the modelling system, the p.Gly2891Asp mutant protein was expressed and show...",10,460,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Val2424Gly,"...The presence of the missense mutation, c.7271T>G (p.Val2424Gly), further increases the risk (Stankov...",21,261,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"Two ATM mutations, c.8672G>A. (p.Gly2891Asp) and c.1A>G (Figure 3), were identifi...",56,32,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...RNA was able to allow translation. The c.8672G>A (p.Gly2891Asp) is a missense mutation located in th...,58,444,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...ells from patient A-T213 came from the c.8672G>A (p.Gly2891Asp) allele. Truncated ATM associated wit...,68,452,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...scured by the full-length ATM from the c.8672G>A (p.Gly2891Asp) allele (Figure 5, compare lanes 5 an...",68,634,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Arg3047X,"...he second allele that was essentially full-length p.Arg3047X (c.9139C>T) (Figure 5, lanes 9 and 10)",68,953,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...in cells of patient A-T213 is from the c.8672G>A (p.Gly2891Asp) allele,70,327,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...mutant protein associated with the c.1A>G and the p.Gly2891Asp mutant protein are shown in Figure 6A...,72,257,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...ant proteins were low, although expression of the p.Gly2891Asp mutant protein was significantly high...",72,581,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...nalyse ATM kinase activity in the higher level of p.Gly2891Asp produced when it was expressed with N...,72,896,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...s expressed with N-terminal tags (Figure 6B). The p.Gly2891Asp mutant protein was autophosphorylated...,72,978,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...eins in A-T213, there was clear evidence that the p.Gly2891Asp mutant protein was active. Consequent...",74,107,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...d presentation, the two ATM mutations, c.8672G>A (p.Gly2891Asp) and c.1A>G, in patient A-T213 are bo...",77,668,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Val2424Gly,"..., were homozygous for the ATM mutation c.7271T>G (p.Val2424Gly). The mutation was also identified in...",85,1052,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Val2716Ala,"...s et al, 2011). Only one ATM mutation (c.8147T>C (p.Val2716Ala)), which also has some ATM kinase act...",87,697,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...ng ATM, the presence of two mutant ATM proteins, (p.Gly2891Asp and the c.1A>G derived protein) raise...",89,313,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...reducing the activity of the more abundant active p.Gly2891Asp protein, using the levels of phosphor...",89,600,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Val2424Gly,...nt ATM protein; this could also apply to both the p.Val2424Gly and the p.Val2716Ala ATM mutations,89,1150,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Val2716Ala,...could also apply to both the p.Val2424Gly and the p.Val2716Ala ATM mutations,89,1171,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.His2555Gln,...mutation (and also null mutation c.7665delinsGTGA;p.His2555Gln ins*) is slightly truncated (lanes 7 ...,112,564,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Arg3047X,...M from c.2T>C in patient AT187 is obscured by the p.Arg3047X (c.9139C>T) mutant protein (lanes 9 and...,112,702,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,... from c.1A>G in patient A-T213 is obscured by the p.Gly2891Asp (c.8672G>A) mutant protein (lanes 5 a...,112,828,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Arg3047X,...ient A-T187 with a c.2T>C mutation and c.9139C>T (p.Arg3047X). (B) Histogram of relative levels of A...,112,1433,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,Figure 6 The p.Gly2891Asp protein has residual ATM kinase activ...,114,14,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...relative to the wt protein (pTAM2, lane 2) or the p.Gly2891Asp protein (8672G>A, lane 5). No ATM pro...",114,481,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...ced levels of both wt protein (pTAM2, lane 2) and p.Gly2891Asp protein (8672G>A, lane 4) were increa...",114,747,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...agged (compare with Supplementary Figure 2A). The p.Gly2891Asp (8672G>A) protein was expressed at a ...,114,894,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,...MEP4) all with N-terminal tags. Expression of the p.Gly2891Asp (8672G>A) protein (lane 5) was compar...,114,1225,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...ble to that of wt ATM (pTAM2, lanes 1 and 7). The p.Gly2891Asp (8672G>A) protein autophosphorylated ...",114,1326,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.Gly2891Asp,"...lation of ATM targets Smc1, KAP-1 and Nbs1 by the p.Gly2891Asp (8672G>A) protein were substantially ...",114,1550,Br_J_Cancer_2012_Jan_17_106(2)_262-268.txt
p.H1047R,GLC82	PIK3CA	p.H1047R	R,128,14,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.E545K,H460	PIK3CA	p.E545K	R,129,13,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.Q61H, 	KRAS	p.Q61H	 ,130,8,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G12S,A549	KRAS	p.G12S	R,131,11,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.Q546K, 	PIK3CA	p.Q546K	 ,132,10,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.Q61K,H1299	NRAS	p.Q61K	S,133,12,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G13D,HCT15	KRAS	p.G13D	R,135,12,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.E545K, 	PIK3CA	p.E545K	 ,136,10,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G12D,LS174T	KRAS	p.G12D	R,137,13,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.H1047R, 	PIK3CA	p.H1047R	 ,138,10,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G12A,GEO	KRAS	p.G12A	S,139,10,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G12V,SW480	KRAS	p.G12V	S,140,12,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G13D,HCT116	KRAS	p.G13D	S,141,13,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.H1047R, 	PIK3CA	p.H1047R	 ,142,10,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.G12V,SW620	KRAS	p.G12V	S,143,12,Br_J_Cancer_2012_May_8_106(10)_1648-1659.txt
p.Arg94X,"...carrying a heterozygous RPS19 mutation (c.280C>T, p.Arg94X), and healthy control samples were from o...",77,289,Br_J_Haematol_2015_Nov_25_171(4)_517-529.txt
p.Ile2047Asn,The presence of one novel missense mutation (p.Ile2047Asn) was analysed in 100 control chromoso...,58,46,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1961Glu,ARDM-135	42	24	0.4	0.6	STGD	c.5882G>A(42)	p.Gly1961Glu	c.1029_1030insT(8)	p.Asn344fsX	NP,76,43,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1961Glu,ARDM-240	15	13	0.2	0.16	STGD	c.5882G>A(42)	p.Gly1961Glu	c.2285C>A(15)	p.Ala762Glu	Yes,77,44,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ala762Glu,....16	STGD	c.5882G>A(42)	p.Gly1961Glu	c.2285C>A(15)	p.Ala762Glu	Yes,77,71,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1961Glu,ARDM-225	32	25	0.25	0.50	STGD	c.5882G>A(42)	p.Gly1961Glu	c.6559C>T(48)	p.Gln2187X	Yes,78,45,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln2187X,....50	STGD	c.5882G>A(42)	p.Gly1961Glu	c.6559C>T(48)	p.Gln2187X	Yes,78,72,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,ARDM-164	21	11	NA	STGD	c.3386G>T(23)	p.Arg1129Leu	c.700C>T(6)	p.Gln234X	Yes,79,38,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln234X,...11	NA	STGD	c.3386G>T(23)	p.Arg1129Leu	c.700C>T(6)	p.Gln234X	Yes,79,63,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,ARDM-162	50	16	0.1	0.1	STGD	c.3386G>T(23)	p.Arg1129Leu	ND	ND	Yes,80,43,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,ARDM-198	27	19	0.1	0.1	STGD	c.3386G>T(23)	p.Arg1129Leu	ND	ND	NP,81,43,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Thr1019Met,ARDM-146	32	13	0.06	0.1	STGD	c.3056C>T(21)	p.Thr1019Met	c.6140T>A(44)	p.Ile2047Asn	Yes,86,44,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ile2047Asn,...0.1	STGD	c.3056C>T(21)	p.Thr1019Met	c.6140T>A(44)	p.Ile2047Asn	Yes,86,71,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Thr1019Met,ARDM-40	46	9	0.1	0.1	STGD	c.3056C>T(21)	p.Thr1019Met	c.3943C>T(27)	p.Gln1315X	Yes,87,41,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln1315X,...0.1	STGD	c.3056C>T(21)	p.Thr1019Met	c.3943C>T(27)	p.Gln1315X	Yes,87,68,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1977Ser,ARDM-90	26	8	Hand moving	STGD	c.5929G>A (43)	p.Gly1977Ser	IVS21-2A>T		Yes,88,46,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1108His,ARDM-181	57	16	0.1	0.09	STGD	c.3323G>A (22)	p.Arg1108His	IVS38+5G>A		Yes,89,45,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ala1598Asp,...DM-197	35	15	0.1	0.1	STGD	c.4793C>A(34) (false +)	p.Ala1598Asp (false +)	c.5172G>T(36)	p.Trp1724Cys	...,90,53,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Trp1724Cys,...4) (false +)	p.Ala1598Asp (false +)	c.5172G>T(36)	p.Trp1724Cys	Yes,90,90,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Leu2027Phe,ARDM-183	63	55	0.150	0.175	STGD	c.6079C>T(44)	p.Leu2027Phe	c.5929G>A(43) (false –)	p.Gly1977Ser ...,91,47,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1977Ser,....6079C>T(44)	p.Leu2027Phe	c.5929G>A(43) (false –)	p.Gly1977Ser (false –)	NP,91,84,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg602Trp,ARDM-38	35	6	0.01	0.02	STGD	c.1804C>T(13)	p.Arg602Trp	c.4739delT(33)	p.Leu1580fs	Yes,92,43,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Pro1486Leu,ARDM-163	48	32	0.01	0.32	STGD	c.4457C>T(30)	p.Pro1486Leu	ND	ND	Yes,93,45,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg2107His,ARDM-166	42	39	NA	STGD	c.6320G>A(46)	p.Arg2107His	ND	ND	Yes,94,38,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val931Met,ARDM-222	26	23	NA	STGD	c.2791G>A(19)	p.Val931Met	ND	ND	NP,95,38,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1640Gln,ARDM-205	NA	NA	NA	STGD	c.4919G>A(35)	p.Arg1640Gln	ND	ND	NP,98,38,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,ARDM-247	30	12	0.05	0.1	CRD	c.3386G>T(23)	p.Arg1129Leu	c.6410G>A(47)	p.Cys2137Tyr	Yes,99,43,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Cys2137Tyr,...	0.1	CRD	c.3386G>T(23)	p.Arg1129Leu	c.6410G>A(47)	p.Cys2137Tyr	Yes,99,70,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val1433Ile,ARDM-99	59	46	0.05	0.05	CRD	c.4297G>A(29)	p.Val1433Ile	ND	ND	NP,100,43,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Thr901Ala,ARDM-131	27	15	0.9	0.7	CRD	c.2701A>G(18)	p.Thr901Ala	ND	ND	Yes,101,42,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,RP-773	38	20	0.05	0.05	RP	c.33N86G>T(23)	p.Arg1129Leu	ND	ND	NP,104,42,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ile156Val,RP-959	53	10	0.1	0.1	RP	c.466A>G(5)	p.Ile156Val	ND	ND	Yes,105,37,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val1433Ile,RP-1058	37	6	0.2	0.6	RP	c.4297G>A(29)	p.Val1433Ile	ND	ND	NP,106,39,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly88Gly,3	c.264 A>T	p.Gly88Gly	This study,113,13,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Asn343Asn,8	c.1029T>C	p.Asn343Asn	This study,117,13,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Glu433Glu,10	c.1299A>G	p.Glu433Glu	This study,118,14,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val552Ile,12	c.1654G>A	p.Val552Ile	This study,119,14,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Pro944Pro,19	c.2832A>G	p.Pro944Pro	This study,121,14,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Leu988Leu,20	c.2964C>T	p.Leu988Leu	18,122,14,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln1169Gln,23	c.3507G>A	p.Gln1169Gln	This study,123,14,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln234X,"...as null mutations: three were nonsense mutations (p.Gln234X, p.Gln1315X “de novo” and p.Gln2187X); t...",130,91,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln1315X,"...ations: three were nonsense mutations (p.Gln234X, p.Gln1315X “de novo” and p.Gln2187X); two splice-s...",130,102,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln2187X,"...se mutations (p.Gln234X, p.Gln1315X “de novo” and p.Gln2187X); two splice-site mutations (IVS22-2A>T...",130,127,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ala762Glu,"...ce (fig 2). Three missense changes were detected (p.Ala762Glu, p.Ile2047Asn and p.Cys2137Tyr) in pat...",130,494,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ile2047Asn,"...hree missense changes were detected (p.Ala762Glu, p.Ile2047Asn and p.Cys2137Tyr) in patients but not...",130,507,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Cys2137Tyr,"...nges were detected (p.Ala762Glu, p.Ile2047Asn and p.Cys2137Tyr) in patients but not in the 100 ethni...",130,524,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ile2142Val,...ntrol chromosomes. We identified the heterozygous p.Ile2142Val change in one out of 100 control chro...,130,640,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Trp1724Cys,"...wo previously described mutations [c.4537delC and p.Trp1724Cys], not included in the array by the ti...",130,870,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1977Ser,"...he time of the screening, and one false negative [p.Gly1977Ser] were detected (1/62; 1.6%)",130,965,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val552Ile,"...ified. Additionally, one novel change in exon 12 (p.Val552Ile) was found in one STGD patient by mean...",134,162,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,"...el ABCA4 variants detected in this screening, the p.Arg1129Leu mutation was found to be the most fre...",138,117,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ala1598Asp,"...longing to family ARDM-197, the chip detected the p.Ala1598Asp mutation. However, dHPLC and direct s...",147,176,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Trp1724Cys,"... not present (false positive). Interestingly, the p.Trp1724Cys mutation was detected by dHPLC in thi...",147,321,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1977Ser,"..., the dHPLC technique led to the detection of the p.Gly1977Ser mutation in the patient from the fami...",147,442,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ala1598Asp,"...rm these results by sequencing, a false positive [p.Ala1598Asp] was identified. Altogether, the comb...",150,196,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1961Glu,"...4–25 years. Moreover, both patients presented the p.Gly1961Glu mutation, which is considered an alle...",154,663,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,The p.Arg1129Leu mutation was found to be the most fre...,167,5,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,"...n previous studies of the Spanish population, the p.Arg1129Leu variant was identified as a major mut...",167,196,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,"...d patient (ARDM-247), double heterozygous for the p.Arg1129Leu and p.Cys2137Tyr alleles, who present...",167,624,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Cys2137Tyr,"...47), double heterozygous for the p.Arg1129Leu and p.Cys2137Tyr alleles, who presented a CRD phenotyp...",167,641,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Cys2137Tyr,"...7Tyr alleles, who presented a CRD phenotype. This p.Cys2137Tyr change was located more towards the a...",167,699,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Cys2137Tyr,...ssociated with an earlier onset of disease.16 The p.Cys2137Tyr change in combination with the p.Arg1...,167,962,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg1129Leu,...6 The p.Cys2137Tyr change in combination with the p.Arg1129Leu allele produced a CRD phenotype. Ther...,167,1006,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Cys2137Tyr,"...phenotype. Therefore, we speculate that the novel p.Cys2137Tyr variant could be a severe allele whic...",167,1091,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1961Glu,"... prevalent missense disease-associated allele was p.Gly1961Glu (3/62; 4.8%), presenting a lower freq...",169,66,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gln2187X,"... least one putative null mutation (c.1030insT and p.Gln2187X), who presented symptoms at the age of ...",169,280,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Gly1961Glu,"... Thus, we could suspect a moderate effect for the p.Gly1961Glu allele, as previously reported.",169,392,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Arg212Cys,"...se, compound heterozygous for the c.3211insGT and p.Arg212Cys variants, showing symptoms at the age ...",171,1262,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val1433Ile,"...enotypes respectively, we identified the missense p.Val1433Ile mutation, located in the second trans...",179,104,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Ile156Val,"...ly analysed by the genotyping microarray, and the p.Ile156Val allele was detected.20 This variant ha...",181,77,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.Val552Ile,"...pected in about 1/50.24 So many variants, such as p.Val552Ile, could be really a mutation found in n...",191,184,Br_J_Ophthalmol_2009_May_21_93(5)_614-621.txt
p.R402C,"...BA1A-associated classic lissencephaly have either p.R402C mutations, resulting in frontal pachygyria...",62,727,Brain_2012_May_16_135(5)_1348-1369.txt
p.R402H,"... and posterior agyria with a cell-sparse zone, or p.R402H mutations, resulting in nearly complete ag...",62,827,Brain_2012_May_16_135(5)_1348-1369.txt
p.Val374Rfs,...Exome	Exon 6 to 8 duplication; c.836-?_1119+?dup; p.Val374Rfs*8	Exon 6 to 8 duplication; c.836-?_111...,103,70,Brain_2013_Jan_3_136(1)_269-281.txt
p.Val374Rfs,...Rfs*8	Exon 6 to 8 duplication; c.836-?_1119+?dup; p.Val374Rfs*8,103,128,Brain_2013_Jan_3_136(1)_269-281.txt
p.Pro149Leu,"...s state: g.chr7: 16255759 T>A, c.446 C>T, causing p.Pro149Leu, which is located in exon 2 and g.chr7...",116,371,Brain_2013_Jan_3_136(1)_269-281.txt
p.Arg126His,"....chr7:16445843 C>T, which is c.377G>A, leading to p.Arg126His. Interestingly, the second compound he...",116,881,Brain_2013_Jan_3_136(1)_269-281.txt
p.Ala53Thr,...found by Sanger sequencing to be c.157G>A causing p.Ala53Thr located in exon 1. All ISPD mutations f...,121,239,Brain_2013_Jan_3_136(1)_269-281.txt
p.Tyr226Cys,...xon 1 and a missense mutation in exon 3 c.677A>G (p.Tyr226Cys). The heterozygous carrier status of t...,123,639,Brain_2013_Jan_3_136(1)_269-281.txt
p.R95H,... y	c.[284G>A] (M) + c.[148G> A];c.[364-1G>A]a (P)	p.R95H (M) + p.E50K;Splice errors a (P)	30 min	Mil...,47,58,Brain_2014_May_18_137(5)_1350-1360.txt
p.E50K,"... (M) + c.[148G> A];c.[364-1G>A]a (P)	p.R95H (M) + p.E50K;Splice errors a (P)	30 min	Mills et al., 20...",47,71,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,"2	5 y 2 m	c.[98A>T] + c.[98A>T]	p.D33V + p.D33V	6 h	Hoffmann et al., 2007",48,34,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,"2	5 y 2 m	c.[98A>T] + c.[98A>T]	p.D33V + p.D33V	6 h	Hoffmann et al., 2007",48,43,Brain_2014_May_18_137(5)_1350-1360.txt
p.P213S,3	2 y 7 m	c.[637C>T] + c.[637C>T]	p.P213S + p.P213S	90 min	Novel,49,36,Brain_2014_May_18_137(5)_1350-1360.txt
p.P213S,3	2 y 7 m	c.[637C>T] + c.[637C>T]	p.P213S + p.P213S	90 min	Novel,49,46,Brain_2014_May_18_137(5)_1350-1360.txt
p.P213S,4*	4 m	c.[637C>T] + c.[637C>T]	p.P213S + p.P213S	None*	Novel,50,33,Brain_2014_May_18_137(5)_1350-1360.txt
p.P213S,4*	4 m	c.[637C>T] + c.[637C>T]	p.P213S + p.P213S	None*	Novel,50,43,Brain_2014_May_18_137(5)_1350-1360.txt
p.R95C,"5	1 y	c.[283C>T] (M) + c.[283C>T] (P)	p.R95C (M) + p.R95C (P)	2 h	Khayat et al., 2008",51,40,Brain_2014_May_18_137(5)_1350-1360.txt
p.R95C,"...	1 y	c.[283C>T] (M) + c.[283C>T] (P)	p.R95C (M) + p.R95C (P)	2 h	Khayat et al., 2008",51,53,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,(ii)	7	6 y 5 m	c.[347G>A] (M) + c.[347G>A] (P)	p.R116Q (M) + p.R116Q (P)	5 m	Novel,53,48,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,...5 m	c.[347G>A] (M) + c.[347G>A] (P)	p.R116Q (M) + p.R116Q (P)	5 m	Novel,53,62,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,(iii)	8	9 y	c.[347G>A] + c.[347G>A]	p.R116Q + p.R116Q	3 h	Novel,54,37,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,(iii)	8	9 y	c.[347G>A] + c.[347G>A]	p.R116Q + p.R116Q	3 h	Novel,54,47,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,"9	2 y	c.[98A>T] + c.[998A>T]	p.D33V + p.D33V	3 w	Hoffmann et al., 2007",55,31,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,"9	2 y	c.[98A>T] + c.[998A>T]	p.D33V + p.D33V	3 w	Hoffmann et al., 2007",55,40,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,"10	23 y	c.[98A>T] + c.[358G>A]	p.D33V + p.E120K	2 m	Hoffmann et al., 2007 + novel...",56,33,Brain_2014_May_18_137(5)_1350-1360.txt
p.E120K,"10	23 y	c.[98A>T] + c.[358G>A]	p.D33V + p.E120K	2 m	Hoffmann et al., 2007 + novel",56,42,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,...1	21 y	c.[98A>T] (P) + c.264-21_ 264-1delinsC (M)	p.D33V (P) + Splice errors (M)	3 h	Hoffmann et al....,57,53,Brain_2014_May_18_137(5)_1350-1360.txt
p.D33V,"12	41 y	c.[98A>T] + c.[347G>A] + c. [673C>T]	p.D33V + p.R116Q + p.R225Cb	14 d	Hoffmann et al., ...",58,47,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,"...1 y	c.[98A>T] + c.[347G>A] + c. [673C>T]	p.D33V + p.R116Q + p.R225Cb	14 d	Hoffmann et al., 2007 + no...",58,56,Brain_2014_May_18_137(5)_1350-1360.txt
p.R225H,13	9 y	c.[674G>A] + c.[674G>A]	p.R225H + p.R225H	24 h	Novel,59,33,Brain_2014_May_18_137(5)_1350-1360.txt
p.R225H,13	9 y	c.[674G>A] + c.[674G>A]	p.R225H + p.R225H	24 h	Novel,59,43,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,... y	c.[347G>A];c.[674G>A] + c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	30 min	Novel,60,56,Brain_2014_May_18_137(5)_1350-1360.txt
p.R225H,...7G>A];c.[674G>A] + c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	30 min	Novel,60,64,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,...74G>A] + c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	30 min	Novel,60,74,Brain_2014_May_18_137(5)_1350-1360.txt
p.R225H,... c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	30 min	Novel,60,82,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,... y	c.[347G>A];c.[674G>A] + c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	10 h	Novel,61,56,Brain_2014_May_18_137(5)_1350-1360.txt
p.R225H,...7G>A];c.[674G>A] + c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	10 h	Novel,61,64,Brain_2014_May_18_137(5)_1350-1360.txt
p.R116Q,...74G>A] + c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	10 h	Novel,61,74,Brain_2014_May_18_137(5)_1350-1360.txt
p.R225H,... c.[347G >A];c.[674G>A]	p.R116Q;p.R225H + p.R116Q;p.R225H c	10 h	Novel,61,82,Brain_2014_May_18_137(5)_1350-1360.txt
p.Leu772*,"...gous frame-shift deletion in CCDC88A (c.2313delT, p.Leu772*ter). Analysis of cDNA extracted from pat...",13,668,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.Leu772X,Figure 2 Discovery of a c.2313delT/p.Leu772X mutation in CCDC88A in individuals with ...,33,36,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.Leu772X,"...ntrol, carrier parent and affected child with the p.Leu772X mutation. (D) Reverse transcriptase poly...",33,642,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.Leu772X,...g a TAG stop codon at the site of the frameshift (p.Leu772X) (Fig. 2B). Segregation of the mutation ...,77,785,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.Leu772X,"... reduced amount of full length mRNA, carrying the p.Leu772X in the lymphocytes of Patient 1 (Fig. 2D...",81,745,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.Leu772X,Having proven the potential pathogenicity of the p.Leu772X mutation in cellular models we asked if ...,84,50,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.Leu772X,...n a frameshift and incorporation of a stop codon (p.Leu772X). Our results confirm an autosomal reces...,92,328,Brain_2016_Apr_25_139(4)_1036-1044.txt
p.E286Q,TP53	5	(10)	17	GAA>CAA/p.E286Q	X	NA	X	Missense	Transversion	1.00	 	Yes,129,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.M246T, 	 	 	 	ATG>ACG/p.M246T	X	NA	X	Missense	Transition	1.00	 	Yes,130,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.E68K, 	 	 	 	GAG>AAG/p.E68K	NA	NA	X	Missense	Transition	0.09	 	ND,131,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.Y234C, 	 	 	 	TAC>TGC/p.Y234C	NA	NA	X	Missense	Transition	0.97	 	ND,132,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.R2605Q, 	 	 	 	CGG>CAG/p.R2605Q	X	X	X	Missense	Transition	1.00	 	No cover...,135,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.M3430I, 	 	 	 	ATG>ATA/p.M3430I	NA	X	X	Missense	Transition	0.00	 	ND,136,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.Y1058C,FBXO38	2	(4)	5	TAT>TGT/p.Y1058C	X	X	X	Missense	Transition	1.00	 	Yes,138,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.E20Q, 	 	 	 	GAA>CAA/p.E20Q	NA	X	X	Missense	Transversion	0.96	 	ND,139,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.E476K,THSD4	2	(4)	15	GAG>AAG/p.E476K	X	X	X	Missense	Transition	1.00	 	Yes,140,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.E652K, 	 	 	 	GAG>AAG/p.E652K	NA	X	X	Missense	Transition	0.96	 	ND,141,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.F303L,TRMT5	2	(4)	14	TTT>CTT/p.F303L	X	X	X	Missense	Transition	0.04	 	Yes,142,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.E152Q, 	 	 	 	GAG>CAG/p.E152Q	NA	X	X	Missense	Transversion	0.03	 	ND,143,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.L540V,PIK3CA	2	(4)	3	CTC>GTC/p.L540V	NA	NA	X	Missense	Transversion	0.99	 	ND,144,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.Q546P, 	 	 	 	CAG>CCG/p.Q546P	NA	NA	X	Missense	Transversion	1.00	 	ND,145,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.A267T,FOXO3	1	(2)	6	GCA>ACA/p.A267T	NA	NA	X	Missense	Transition	0.97	 	ND,146,23,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.P292S, 	 	 	 	CCT>TCT/p.P292S	NA	NA	X	Missense	Transition	0.34	 	ND,147,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.L528V, 	 	 	 	TTG>GTG/p.L528V	NA	NA	X	Missense	Transversion	0.03	 	ND,148,17,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.R674C,BBS12	1	(2)	4	CGC>TGC/p.R674C	X	X	X	Missense	Transition	1.00	 	Yes,149,23,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.P77S,BBS9	1	(2)	7	CCA>TCA/p.P77S	X	X	X	Missense	Transition	1.00	 	No coverag...,150,22,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.D1420N,CASP8AP2	1	(2)	6	GAT>AAT/p.D1420N	X	X	X	Missense	Transition	1.00	 	No cover...,151,26,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.A406T,EIF2B5	1	(2)	3	GCA>ACA/p.A406T	X	*	X	Missense	Transition	0.05	 	Yes,152,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.A659P,FMN2	1	(2)	1	GCT>CCT/p.A659P	X	*	*	Missense	Transversion	0.74	 	No cove...,153,22,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.T468M,HSP90B1	1	(2)	12	ACG>ATG/p.T468M	X	 	X	Missense	Transition	0.98	 	Yes,154,26,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.D571Y,IKBKE	1	(2)	1	GAC>TAC/p.D571Y	X	*	X	Missense	Transversion	0.68	 	Yes,155,23,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.N167S,PCF11	1	(2)	11	AAT>AGT/p.N167S	X	X	X	Missense	Transition	0.02	 	Yes,156,24,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.K279N,PLCL1	1	(2)	2	AAG>AAT/p.K279N	X	X	X	Missense	Transversion	0.98	 	No cove...,157,23,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.R864L,PTPN21	1	(2)	14	CGA>CTA/p.R864L	X	X	X	Missense	Transversion	1.00	 	Yes,158,25,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.R217C,SEC63	1	(2)	6	CGC>TGC/p.R217C	NA	X	X	Missense	Transition	1.00	 	ND,159,23,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.D339A,ST7L	1	(2)	1	GAT>GCT/p.D339A	X	X	X	Missense	Transversion	1.00	 	Yes,161,22,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.N3400K,UBR4	1	(2)	1	AAC>AAA/p.N3400K	X	X	X	Missense	Transversion	0.98	 	Yes,163,22,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.Q1582P,ZFYVE26	1	(2)	14	CAA>CCA/p.Q1582P	X	X	X	Missense	Transversion	0.00	 	Yes,164,26,Breast_Cancer_Res_2014_May_8_16(3)_R46.txt
p.V637E,The mouse Braf p.V637E missense mutant protein is the murine coun...,129,16,Cancer_Cell_2013_Jul_8_24(1)_15-29.txt
p.V600E,...otein is the murine counterpart of the human BRAF p.V600E oncogenic variant. V637 is encoded in Braf...,129,92,Cancer_Cell_2013_Jul_8_24(1)_15-29.txt
p.Y657S,...er and activator of transcription 3 (STAT3) gene (p.Y657S) Eur. J. Pediat. 2011 170 661 666 10.1007/...,129,230,Cancers_(Basel)_2014_Mar_6_6(1)_494-525.txt
p.V600E,...ical staining for BRAFV600E mutation. We detected p.V600E-mutated cells in the perivascular region o...,12,970,Case_Rep_Dermatol_2015_Sep_12_7(3)_237-240.txt
p.V600E,...drochloride and its enhancer. We could not detect p.V600E mutation in the BRAF gene by quantitative ...,17,999,Case_Rep_Dermatol_2015_Sep_12_7(3)_237-240.txt
p.V617F,7 Lange T.  Edelmann A.  Siebolts U.    JAK2 p.V617F allele burden in myelo proliferative neopl...,53,46,Case_Rep_Hematol_2015_Aug_9_2015_703457.txt
p.Ser459Ter,"c.1376C>G, p.Ser459Ter",52,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Trp897Ter,"c.2691G>A, p.Trp897Ter",55,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Arg277Ter,"c.829C>T, p.Arg277Ter",65,11,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Tyr328Ter,"c.984C>A, p.Tyr328Ter",67,11,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Arg630X,"c.2455C>T, p.Arg630X",68,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Arg1488X,"c.4462C>T, p.Arg1488X",70,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Trp1689X,"c5067G>A, p.Trp1689X",71,11,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Glu693X,"c.2076_2077InsT, p.Glu693X",72,18,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Lys1450X,"c.4975A>T, p.Lys1450X",75,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.K376Q,"c.1126A>C, p.K376Q",79,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Y328X,"c.984C>A, p.Y328X	Ahmad et al., 2007 [15]",85,11,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.R896Q,"c.2687G>A, p.R896Q",89,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Arg523Ter,"c.1567C>T, p.Arg523Ter	Kurban et al., 2010 [17]",96,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Met899Ile,"c.2697G>A, p.Met899Ile",100,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Met932Leu,"c.2796A→C, p.Met932Leu",102,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Arg523Ter,"c.1567C>T, p.Arg523Ter",112,12,Case_Rep_Neurol_Med_2014_Sep_18_2014_141953.txt
p.Gly1200Ser,"...erozygous mutation in the COL2A1 gene (c.3598G>A; p.Gly1200Ser). This missense mutation, creating a ...",26,174,Case_Rep_Obstet_Gynecol_2015_Sep_8_2015_935204.txt
p.L541P,"... in the ABCA4 gene with complex allele c.1622T>C, p.L541P; c.3113C>T, p.A1038V in homozygous state",15,670,Case_Rep_Ophthalmol_Med_2015_Jul_2_2015_452068.txt
p.A1038V,"...ith complex allele c.1622T>C, p.L541P; c.3113C>T, p.A1038V in homozygous state",15,690,Case_Rep_Ophthalmol_Med_2015_Jul_2_2015_452068.txt
p.L541P,"... in exons 12 and 21 of the ABCA4 gene (c.1622T>C, p.L541P; c.3113C>T, p.A1038V), (2) a heterozygous ...",29,599,Case_Rep_Ophthalmol_Med_2015_Jul_2_2015_452068.txt
p.A1038V,"...of the ABCA4 gene (c.1622T>C, p.L541P; c.3113C>T, p.A1038V), (2) a heterozygous variant in exon 2 of...",29,619,Case_Rep_Ophthalmol_Med_2015_Jul_2_2015_452068.txt
p.K249N,...ygous variant in exon 6 of the RGR gene (c.747A>T p.K249N). Based on previous knowledge of these thr...,29,772,Case_Rep_Ophthalmol_Med_2015_Jul_2_2015_452068.txt
